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INTRODUCTION 
The elder population is one that is frequently overlooked or 
excluded in drug studies. However, although those over 65 years of 
age constitute approximately 12% of the total population, they take 
25% of all prescription medications.1 The elderly may have many and 
varied reactions to drugs as compared to a younger population. These 
differences may be pharmacokinetic or pharmacodynamic in nature. 
Unfortunately, the amount of available Information concerning pharma-
cokinetic and pharmacodynamic changes due to aging is limited. The 
pool of knowledge in respect to tolerance or sensitivity to narcotic 
analgesics in the geriatric patient is also limited. Until now no 
prospective controlled studies have Investigated the subjective and 
objective response of narcotic analgesics in the elderly. 
Butorphanol tartrate Is a totally synthetic analgesic with 
agonist/antagonist properties. It Is derived from the morphinan 
chemical series and is chemically designated as levo-N-cyclobutyl-
methyl-3, 14 B - dihydroxymorphine. Postoperative pain studies have 
2-5 
shown equipotent analgesia of butorphanol with morphine , 
6—8 9—13 meperidine , and pentazocine. Butorphanol is five to eight 
5 
times more potent than morphine sulfate ; 30-50 times more potent 
than meperidine'''^; and 16-20 times more potent than pentazocine.^' 
Butorphanol has approximately the same antagonist potency as nalor-
14 
phine and 1/40 the antagonist potency of naloxone. 
The manufacturer's recommended dose of butorphanol tartrate is 
1-2 mg intramuscularly. It has an onset of ten minutes and a peak 
effect within 30-60 minutes. The duration of analgesia is typically 
2 
3-4 hours, but can be 2-6 hours depending on patient size, pain 
15 
stimulus, and environmental influences. These parameters are 
16 
similar to those of morphine sulfate. The maximum serum concen-
tration of butorphanol from a 2 mg intramuscular injection after 
30-60 minutes is 2.2 ng/ml. Butorphanol is approximately 801 protein 
bound. It is metabolized by the liver through the following pathways: 
1) hydroxylation of the cyclobutylmethyl group (60-80%); 2) glucuro-
nide conjugation at the 3-hydroxy position (less than 10%) ; and 3) 
O-dealkylation of the cyclobutylmethyl group (5-10%). None of the 
metabolites possess analgesic properties. Less than 5% is excreted 
in the urine unchanged. Approximately 75% of the drug or its 
metabolite's are recovered in the urine within 72-96 hours after 
intramuscular administration. In addition to urinary excretion, 
11-14% of the drug is eliminated via biliary excretion.^ 
Opiate analgesic drugs and agonist/antagonist compounds share 
the same basic scope of side effects. Dizziness and light-headedness 
are reported in less than 1% of patients. Sedation is the most 
common side effect and is dose related ranging in frequency from 
17 
0-92%. Therapeutic doses of 1-2 mg of butorphanol produce sedation 
in 10-25% of patients which is similar to that of the other 
3-5 
opiates. Paradoxically central nervous system excitation or 
psychomimetic effects are also possible and have been reported in 
1-2% of patients. These central nervous system effects include 
varied reactions such as euphoria, confusion, agitation or unusual 
dreams."*""5 Nausea is experienced by 0-10% of patients when butor-
phanol tartrate is used for postoperative pain or for balanced 
3-5 
anesthesia. Constipation does not usually occur during short term 
3 
use. Skin rashes and pain at the injection site are rarely reported. 
Sweating or diaphoresis and -miosis are possible, but seldom observed. 
15 
Dysuria is rare even in renal colic patients. Lippman and 
colleagues noted that 2 mg of butorphanol tartrate produced compar-
4 
able respiratory depression to 10 mg morphine sulfate. With 
increasing doses of butorphanol between 2 and 4 mg, respiratory 
depression increases only minimally. No increase in respiratory 
depressant effects was noted above 4 mg suggesting a "ceiling 
effect".^ Hemodynamically butorphanol may also differ from morphine. 
18 
Popio and colleagues compared intravenous morphine and butorphanol 
in 20 patients during diagnostic cardiac catherization who averaged 
50 years of age. Butorphanol produced less hypotension than mor-
phine, and it caused an increase in the cardiac index (CI). The 
authors concluded that the increased CI was related to an increase 
stroke volume rather than an increased heart rate. The doses for 
morphine and butorphanol were 0.025 and 0.125 >Jg/kg respectively. 
An additional concern with narcotic analgesics is their abuse 
liability. Butorphanol demonstrates a lower dependence potential 
than „ r p h l n e , p»t...ci=. 0r deKt^prop^pharu,19 During phase III 
clinical trials, butorphanol was administered chronically at thera-
peutic doses to patients for as long as nine months and then abruptly 
terminated. No withdrawal symptoms or compulsive drug seeking 
20 
behavior were precipitated. 
Clinical evidence suggests that the elderly are more sensitive 
to toxic and therapeutic effects of drugs than younger patients. 
21 
Hurwitz surveyed two Belfast hospitals for one year. One thousand, 
two hundred and sixty-eight patients were admitted to the hospital 
4 
for adverse drug reactions (ADR). The ADR occurrence was seven times 
greater for patients over 60 years of age, Schumucker''" concurred 
with this finding and estimated that the likelihood of ADR in the 
aged patient is three to seven times greater than in the younger 
patient. 
The elderly may also be more sensitive to the toxic effects of 
22 
narcotic analgesics. Cardoc-Davies reported on 450 admissions to a 
hospital geriatric unit. All patients studied were 75 years of age 
or older. Seven patients were admitted for opiate toxicity mani-
fested as the triad of symptoms: pinpoint pupils, low level of 
23 
consciousness, and depressed respirations. Leach and Roy monitored 
521 consecutive admissions to an acute geriatric unit. All drugs 
given to these patients and all occurrences of ADR were recorded. 
From this compilation more ADR were noted in patients over 80 years 
of age than in those less than 80 years of age. This study also 
showed that diuretics and diamorphine had the highest risk of ADR 
with diamorphine producing the highest rate of severe ADR, especially 
respiratory arrest. 
The differences between older and younger patients with respect 
to medication response are likely due to pharmacokinetic and pharma-
codynamic age-related differences. The intensity and duration of 
drug action depends upon the concentration of free drug at the site 
of cellular action and on the sensitivity of the target organ. 
Pharmacokinetics describe the time course of drug action in the body 
and includes quantitative study of drug absorption, distribution, and 
elimination. Normal aging and many diseases encountered in the 
elderly generally affect drug kinetics in such a way as to cause an 
Increased concentration of free drug at the sites of cellular action. 
Pharmacodynamics describes the biological and therapeutic effects of 
drugs and is concentration independent and subcellular in nature. 
While this aspect of pharmacology has been studied less intensively 
than kinetic changes, there is some evidence of increased tissue 
22 
sensitivity in old age. 
Age-related physiologic changes that may affect the pharmaco-
24-33 
kinetics of drugs have been well described. Absorption of drugs 
from the gastrointestinal tract appear unchanged with age.26'28 
However, intramuscular absorption may be slowed due to decreased 
29 
peripheral circulation. Drug distribution may be altered due to 
reductions in total body water and lean body mass coupled with 
26 27 
increases in total body fat associated with aging. ' Additional-
30 
ly, age-related increases in alpha-l-glycoprotein and reductions in 
31 32 albumin may alter plasma protein binding of highly bound drugs. " 
Lastly, drug elimination may be reduced secondary to either reduced 
renal clearance25 or impaired hepatic metabolism.33 
34 
Stanski and colleagues studied the pharmacokinetics of 10 mg 
of morphine given intramuscularly or intravenously in eight young 
healthy volunteers and four elderly preoperative patients (61 to 81 
years of age). A decrease in morphine clearance was observed in the 35 
elderly group. Holmberg and colleagues compared the disposition of 
meperidine in six young patients with a mean age of 26.4 years versus 
nine elderly patients with a mean age of 74.4 years. Pharmacokinetic 
analysis demonstrated a decrease in meperidine clearance in the 
elderly group. Protein binding of meperidine has been shown to 36
decrease as a function of age. Therefore, the data with commonly 
6 
used narcotic analgesics generally supports the pharmacokinetic 
rationale for reduced doses of these drugs in the elderly. "However, 
37 
Ramsey and colleagues evaluated the pharmacokinetics of intravenous 
butorphanol in a single-dose study involving eight young and nine 
relatively healthy elderly volunteers. Although no significant 
differences in disposition and elimination were noted between the two 
groups, a longer elimination half-life in connection with a small 
decrease in the rate of clearance and an increased volume of distribu-
tion were noted in the elderly patients. The elderly volunteers 
tolerated the 2 mg dose of butorphanol well and experienced minimal 
adverse reactions. Notably, the elderly experienced no central 
nervous system disturbances such as confusion, euphoria, or dysphoria. 
However, the clinical applicability of these results to a patient 
population remained to be tested. 
OBJECTIVE 
The purpose of this study is to evaluate the analgesic activity 
and possible side effects of butorphanol tartrate in comparison with 
morphine sulfate, when administered to geriatric postoperative 
patients experiencing moderate to severe pain. 
METHODS 
Forty male and female patients 60 years of age or older were 
enrolled in this double-blind randomized study in accordance with the 
criteria specified below. Sixty patients will be enrolled upon 
completion of the study. These patients were from either the 
University Hospital or Veterans Administration Hospital, Salt Lake 
7 
City, Utah. Informed consent (Appendix A) was obtained the day prior 
to surgery. Consent by the attending surgeon was received before 
approaching the patient. Most had given blanket consent prior to the 
initiation of the study. Some physicians limited their consent to 
certain procedures and others requested they be contacted on a case 
by case basis. Acceptable operations for the study consisted of any 
surgical procedure requiring a general anesthetic which was likely to 
produce pain postoperatively and require hospital admission for at 
least 24 hours. 
Patients were excluded from the study if any of the following 
conditions existed: 
1) History of previous hypersensitivity or severe adverse drug 
reaction to opiate analgesics or butorphanol; 
2) History of narcotic drug addiction, tolerance, or abuse; 
3) History or presence of hepatic insufficiency; 
4) Decompensated congestive heart failure per the New York 
Heart Association Classification - Class III or IV; 
5) Pre-existing pulmonary vascular complications, such as 
pulmonary embolism or cor pulmonale; or 
6) Moderate to severe chronic obstructive pulmonary disease. 
Materials 
Butorphanol tartrate 2 mg/ml (10 ml vials) and morphine sulfate 
15 mg/ml (20 ml vials) were purchased through the normal distribution 
channels at University Hospital. The butorphanol solutions were 
prepared by the University Hospital I.V. Center with bacteriostatic 
water in the following concentrations 1 mg/ml in 1 ml vials, 2 mg/ml 
in 1 ml vials, and 2 mg/ml in 6 ml vials. The morphine solutions 
8 
were available in the following concentrations 4 mg/ml in 1 ml vials, 
8 mg/ml in 1 ml vials and 8 mg/ml in 6 ml vials. Each of the 1 ml 
and 6 ml vials were identical in appearance. Inventory control and 
dispensing of the study drugs were the responsibilities of the 
Department of Pharmacy Services, University Hospital, 
Randomization 
Patients were randomized using a random numbers table to receive 
an initial dose of 1 or 2 mg of butorphanol or 4 or 8 mg of morphine. 
The confidential coding key was accessible only to the Drug Research 
Coordinator and the University Hospital I.V. Center pharmacists. 
Procedure 
Patients began the study upon recovering from anesthesia and 
arriving on a surgical or medical ward and complaining of pain. One 
observer asked the patient to rank the intensity of their pain (scale 
explanations below). Those reporting either no pain or mild pain 
were discontinued from the study and received other appropriate 
medications by order of the primary physician. Patients reporting 
moderate to severe pain and requesting medication were randomly 
assigned to receive a 1 ml intramuscular injection containing one of 
the following treatments: 1 mg butorphanol tartrate, 2 mg butor-
phanol tartrate, 4 mg morphine sulfate, or 8 mg morphine sulfate. 
Subsequent dosages of the study medication were adjusted to the 
clinical need of the individual patient. The recommended dosage 
guidelines were 1-2 mg of butorphanol tartrate (0.5-1 mg of 2 mg/ml 
solution) or 4-8 mg of morphine sulfate (0.5-1 ml of 8 mg/ml 
solution) administered intramuscularly every two to three hours as 
requested for pain control. To maintain double-blinding and allow 
9 
for clinical titration of doses, a separate supply of study medica-
tion containing 6 ml of either butorphanol tartrate 2 mg/ml or 
morphine sulfate 8 mg/ml was provided according to initial patient 
randomization. 
Monitoring was done by the same investigator throughout the 
immediate postoperative period. Pain intensity was evaluated by the 
patient at baseline, one-half hour post-dose and then at hourly 
intervals for a maximum of six hours post-dose. Two scales were used 
to assess pain intensity: 1) the Present Pain Intensity Scale 
O O 
(PPIS) and 2) a Visual Analog Scale (VAS). The PPIS consists of 
six pain intensity descriptors: no pain (0), mild (1), discomforting 
(2), distressing (3), horrible (4), and excruciating (5) (Appendix 
B). The VAS is a 10 centimeter line labeled at one end with "No 
pain" and the other end "Pain as bad as it could be" (Appendix C). 
The distance on the VAS measured in millimeters allows quantification 
of the pain intensity at an interval level of data.39 
Pain relief was assessed by a six point descriptive/ordinal 
scale (Appendix D). Patients were asked to evaluate pain relief 
following administration of study drug at the same times as for pain 
intensity. The scale was as follows: complete relief (4), a lot of 
relief (3), moderate relief (2), a little relief (1), no relief (0), 
40 
or the pain is worse (-1) . 
A pulse oximeter monitoring devise was placed on the index 
finger of each patient who received study medication. The device 
continuously monitored oxygen saturation. Documentation of the 
oxygen saturation was made every 15 minutes for one-half hour and 
then every hour for a maximum of six hours. 
10 
Vital sign measurements consisting of blood pressure, pulse and 
respiratory rate for each patient were recorded at the following 
times: 1) pre-dose, 2) every 15 minutes for one-half hour, and 3) 
every hour for a maximum of six hours post-dose. 
Assessment of sedation was made by the observer at the same 
times described above for vital sign measurements. A four level 
ordinal scale was employed: none, fully awake (0); drowsy, sleepy 
but responsive to various background noises (1); somnolent, appears 
asleep but responds to direct verbal commands (2); or asleep (3) 
(Appendix E) 
Following the initial observation period, patients continued to 
receive the analgesic assigned to them for up to 72 hours as neces-
sary for pain relief. Adverse effects were documented throughout the 
study. Adverse effects were documented by one of the following 
methods: 1) questioning the patient; 2) reviewing the physicians' 
and nurses' notes; and 3) direct observations by one of the 
investigators. 
Analysis 
Statistical analysis is limited to descriptive treatment of the 
data. The investigation will continue to be blinded until the study 
is finished in Its entirety at the completion of 60 patients. 
Pain intensity difference (PID), pain analog intensity differ-
ence (PAID), and sedation (SED) scores were calculated by subtracting 
the score after dosing from that at baseline. Sum of the pain 
intensity difference (SPID), sum of the pain analog intensity differ-
ence (SPAID), sum of sedation differences (SSED) and total pain 
11 
relief (TOTPAR) scores were determined as cumulative measures of 
overall effects by taking weighted sums of the respective PID, PAID, 
SED, and pain relief scores (the weights equaled the proportions of 
an hour since the proceeding observation). Spearman Rank Correla-
tions between SPID, SPAID, and TOTPAR were calculated and linear 
comparisons between the parameters established. All means were 
derived and reported with appropriate standard deviations. 
Adverse drug reactions (ADR) were assessed for probability of 
42 
causality by an algorithm developed by Hutchinson et al (Appendix 
F). ADR were also compared to age and the number of study drug doses 
patients received. Correlations between these parameters were noted. 
Vital signs and oximetry were assessed for time patterns of change or 
clinically significant changes. 
RESULTS 
Demographics 
As of March 31, 1987, 40 surgical patients had completed the 
study. Twenty-two females and 18 males were studied. The mean age 
of this group was 69.3 ± 7.1 years ranging from 60 to 87 years. The 
mean age of the females was 69.7 ± 7.9 years ranging from 60 to 87 
years. The mean age of the males was 68.7 ±6.2 years ranging from 
60 to 85 years. Specific patient characteristics are reported in 
Table 1. 
The subjects that participated in this investigation had numer-
ous chronic disease states. The average number of chronic problems 
per patient was 2.98 + 1.6 problems ranging from one to six problems. 
12 
These chronic problems included; rheumatoid arthritis or osteoarth-
ritis, hypertension, cardiac arrhythmias, coronary artery disease, 
adult onset diabetes mellitus, various types of cancer, chronic 
obstructive pulmonary disease, hypothyroidism, peptic ulcer disease, 
genitourinary dysfunction, and cerebrovascular disease. 
The surgeries for the 40 patients are enumerated in Table 1. 
Anesthetic for these procedures was by choice of the anesthesiologist. 
Most patients received isoflurane, fentanyl, or nitrous oxide alone 
or in combination. Specific anesthetics are listed in Table 1. 
Pain Intensity, Pain Relief, Sedation and Dose Analysis 
Time lines in Appendix G illustrate the verbal pain intensity 
scale, visual analog scale, pain relief and sedation scale readings 
for each subject during the observation period. 
The mean initial pain intensity was 3.1 ± 0.9 ranging from 2.0 
to 5.0. The summation of the pain intensity difference (SPID), which 
is the summation of the pain intensity difference weighted by time, 
at one hour averaged 1.6 ± 1.4 ranging from -2.5 to 5.5. One hour 
averages were calculated since this would be the expected peak anal-
gesic effect from both butorphanol and morphine. The average SPID 
for the first dose was 7.4 ± 14.3 ranging from -6.0 to 76.8. The 
summation of the pain analog difference (SPAID) at one hour, which is 
the summation of the PAID weighted by time, averaged 25.0 ± 26.6 
ranging from -41.0 to 106.5. The mean SPAID for the first dose was 
123.9 ± 290.1 ranging from -91.0 to 1682.5. Total pain relief 
difference (TOTPAR) at one hour averaged 4.5 ± 13.4 ranging from -0.5 
to 84.5. The TOTPAR for the first dose averaged 11.6 ± 16.8 ranging 
from -0.5 to 84.5. lor all measures above, negative values indicate 
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increased pain or lack of pain relief whereas the more positive 
values indicate greater pain relief and lessening of pain. For 
specific patient data refer to Table 2. 
Coefficients of correlation were calculated by a Spearman Rank 
Correlation for SPID, SPAID and TOTPAR. The r values for SPID vs. 
SPAID, SPID vs. TOTPAR, and SPAID vs. TOTPAR were 0.77, 0.82 and 
0.71, respectively. 
The sedation difference (SED) at one hour was -1.59 ± 2.49 
ranging from -5.25 to 2.5. The first dose summation of sedation 
difference (SSED) averaged -3.57 ± 7.9 ranging from -23.5 to 3.0. 
The negative values indicate increased sedation, and positive numbers 
show a decrease in sedation or the patient became more alert as 
compared to baseline. Specific sedation data per each patient are 
listed in Table 2. 
The mean time until redosing was 2.98 ± 2.7 hours ranging from 
0.92 to 14.8 hours. The mean total number of doses was 10.5 ± 6.8 
doses ranging from 1 to 24 doses. The mean total number of milli-
liters was 9.3 ± 6.8 mis ranging from 1,0 to 24,5 mis. The mean 
number of doses received during the observation period was 2.1 ± 0.67 
doses ranging from one to four doses. The corresponding mean number 
of milliliters was 2.0 ± 0.67 mis ranging from 1 to 4 mis. The mean 
number of doses during the first 24 hours was 4.3 ± 2.2 doses ranging 
from one to eight doses with a mean number of milliliters of 3.9 ± 
2,4 mis ranging from 0.5 to 8.5 mis. The mean number of doses during 
the 48 hour period was 4.0 ± 2.0 doses ranging from one to nine 
doses. The mean number of milliliters during the 48 hour period was 
3.7 ± 2.4 mis ranging from 0,5 to 9.0 mis, The mean number of doses 
14 
for the 72 hour period was 3.9 ± 1.7 doses ranging from one to six 
doses with a mean number of milliliters of 3.8 ± 2.0 mis ranging from 
1.0 to 8.0 mis. The total number of doses and milliliters received 
by each patient are listed by patient in Table 3. 
Pain Analysis for Various Surgical Groups 
Seven patients who underwent total knee arthroplasties had a 
mean pain intensity of 3.4 ± 1.1 ranging from 2.0 to 5.0. The first 
dose duration mean was 1.6 ± 0.7 hours ranging from 1.0 to 3.0 hours. 
The mean number of doses for this group was 12.1 ±8.1 doses ranging 
from 1 to 22 doses and a mean total milliliters of 12.3 ± 8.5 mis 
ranging from 1,0 to 24,5 mis. 
Seven patients who underwent total hip arthroplasty had a mean 
initial pain intensity of 3.3 ± 0.8 ranging from 2.0 to 4.0. The 
mean time to redosing was 3.2 ± 1.5 hours ranging from 1.0 to 5.45 
hours. The mean total number of doses was 10.9 ± 1.6 doses ranging 
from 4 to 21 doses, with a mean total number of milliliters of 8.8 ± 
5.6 mis ranging from 3.0 to 19.5 mis. 
Six patients had colectomies and a mean initial pain intensity 
of 3.7 ± 0.8 ranging from 3.0 to 5.0. The time to redosing mean was 
2.3 ±1.9 hours ranging from 1.08 to 6.06 hours. The total dose mean 
was 12 ± 4.7 doses ranging from 4 to 18 doses, with an average amount 
of 9.9 ± 4.7 mis ranging from 4 to 18 mis. 
Four patients had laminectomies with a mean initial pain inten-
sity of 3.5 ± 1.3 ranging from 2.0 to 5.0. The time to redosing mean 
was 3.5 ± 3,1 hours ranging from 1.25 to 7,83 hours. Total dose mean 
was 15.5 ± 9.1 doses ranging from 2 to 21 doses, with an average num-
ber of milliliters of 14.9 ± 9.05 mis ranging from 1.5 to 21.0 mis. 
Three patients had total abdominal hysterectomies with bilateral 
salpingo oophorectomies. Their mean initial pain intensity was 3.0 ± 
1.0 ranging from 2.0 to 4.0. The time to redosing mean was 2.1 ± 0.8 
hours ranging from 1.20 to 2,83 hours. Total doses averaged 5.3 + 
1,5 ranging from four to seven with an average number of milliliters 
of 3.9 ± 1.3 mis ranging 3.0 to 5.3 mis. Table 4 includes specific 
patient data. 
Vital Sign Assessment 
The greatest change in blood pressure, respirations, pulse, and 
oximetry readings were noted during the observation period. Ordinal 
numbers were assigned to the various time intervals between measure-
ments. Initial time to 15 minutes was designated as #1; 15 minutes 
to 30 minutes as #2; 30 minutes to one hour as #3; one hour to two 
hours as #4; two to three hours as #5; three to four hours as #6; 
four to five hours as #?; and five to six hours as #8. 
Blood pressure was assessed for the greatest change noting 
either a hyper- or hypotensive response. The change may or may not 
have been clinically significant. The greatest change occurred 
during the time interval #3 for 11 of the 40 patients. Nine of 40 
showed their greatest change at interval #4 and eight patients showed 
differences during the first 15 minutes of observation or interval 
#1. For the remainder of the patients, five had fluctuations at 
interval #2, four during interval #5, two during interval #6, none 
during interval #7 and only one patient had the greatest change 
during interval #8. Patient 15 showed the greatest increase in blood 
pressure from 120/86 to 176/100 mrr.Hg which occurred during interval 
#6. This was felt to be insignificant because she was hypertensive 
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prior to the administration of the study medication. Patient 40 
showed the greatest decrease in pressure from 125/80 to 80/55 mmHg 
during interval #4. This occurrence was probably due to other 
physiological problems. However, this particular hypotensive episode 
resolved without treatment. See Table 5 for patient specific changes 
and intervals. 
Respirations were also assessed for the greatest change noting 
either increased or decreased responses. Again the differences may 
not have been clinically significant. Ten patients demonstrated 
changes in both the first and second intervals. Seven patients had 
the greatest change in respirations in interval #3, six patients in 
interval #4, three patients in interval #5, two in interval #6 and 
two patients had no changes in respiration throughout the observation 
period. Three patients demonstrated decreases of eight respirations 
per minute. Patient 4 and Patient 35 had a decrease in respirations 
from 20 to 12 breaths per minute during interval #1 and Patient 10 
went from 19 to 11 breaths per minute during interval #4. Patient 8 
had the greatest increase in respirations from 14 to 24 which occurred 
in interval #2. Patient 10 had a consistent respiration rate between 
10 to 11 breaths per minute but these readings occurred between 2400 
and 0300 when the patient was somnolent and resting. Patient 14 was 
told to deep breathe when his respirations dropped and they immed-
iately returned to 16 breaths per minute without further treatment. 
Patient specific changes and time intervals are listed in Table 6. 
Pulse was also assessed in the same manner. Twelve patients 
showed the greatest change during interval #1. Seven patients had 
noted changes interval #2, four in interval #3, six each in intervals 
//4 and #6 and five patients in interval //5. Patient 15 showed the 
largest increase in pulse which occurred during interval #5 from 69 
to 90 beats per minute. Patient 5 showed the greatest decrease which 
occurred during interval #4 from 120 to 103 beats per minute. None 
of the pulse changes were clinically significant. Pulse changes for 
each subject are listed in Table 7. 
Oximetry readings were also assessed. Three patients did not 
have readings due to the patients* refusals to wear the oximeter or 
due to machine malfunctionings. Twelve patients experienced the 
greatest change during interval #1, four during interval #2, five in 
intervals #3 and #5, eight in interval #4, two in interval #6, and 
one patient in interval Hi.  Patients 4 and 35 had the greatest de-
crease in oximetry readings. Patient 4 experienced a decrease from 
100 to 90% during interval #1 and Patient 35 experienced a decrease 
from 93 to 83% during interval #4. Patient 3 had the greatest 
increase in readings from 85 to 97% during interval #4. Patient 
specific changes are reported in Table 8. 
Adverse Reactions 
Several subjects experienced adverse reactions. Seven patients 
were withdrawn from the study at some point during the 72 hour study 
period by physicians, family members, or by their own request (Tables 
9 and 10), Patient 2 and Patient 14 were withdrawn because family 
members felt pain relief to be inadequate. Patient 5 was felt to be 
excessively sedated by her physician and was subsequently withdrawn. 
Patient 21 was experiencing significant central nervous system side 
effects (agitation and personality changes) and was withdrawn by 
family and physicians' request. Patient 22 felt the drug made him 
"dopey" and did not want to continue with the study. Patient 32 was 
having painful headaches that were not improving with the study 
medication and asked to be withdrawn from the study. Patient 40 was 
very unstable. In order to reduce the number of variables affecting 
this patient's status, the patient was withdrawn from the study by 
his physician. Thus, 7/40 or 17.5% of patients were withdrawn from 
the study due to adverse drug reactions (ADR). Descriptive summaries 
of these patients and other subjects are listed in Appendix H, 
Table 9 lists all side effects noted for the observation period 
and the first 24 hours. Table 10 lists all side effects noted for 
the 48 hours and 72 hours intervals. Nausea frequently occurred and 
was noted in 22 of the 40 subjects (55%) during the 72 hours of the 
study. Vomiting occurred in seven (17.5%) of these patients. 
Eighteen patients (45%) experienced dry mouth. Eleven patients 
(27,5%) had some episodes of vertigo or dizziness and six patients 
(15%) had pruritus. Six patients (15%) also experienced dysphoria or 
confusion. Five patients (12.5%) had diaphoresis. Three (7.5%) 
complained of lethargy and one (2.5%) complained of diaphoresis and 
flushing. Only two patients (5%) noted blurred vision. Other less 
expected adverse reactions consisted of five patients (12.5%) with 
headaches, eight patients (20%) with insomnia, and two (5%) noted 
tinnitus. 
All reported adverse effects were evaluated for total probabil-
ity that the study drug was the cause of the adverse reaction by an 
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algorithm developed by Hutchinson and colleagues, The likelihood 
of adverse reactions is as follows: probable - 47/174 (27%); possi-
ble - 104/174 (60%); unlikely - 23/174 (13%). Twenty-eight of the 
19 
174 ADR (16%) were attributed to the five patients who eventually 
were withdrawn from the study. Of these 28 ADR, 15 or 54% were 
assessed as probable, 12 or 43% were rated as possible, and 1 or 3% 
was rated as unlikely. 
Fifteen percent of all ADR required treatment. Ninety-one 
percent of these were nausea and vomiting. Patients 18,25,29,30,32, 
39 and 40 received treatment with droperidol. Patient 21 and Patient 
26 were treated with promethazine. Patient 40 was also treated with 
naloxone for his central nervous system manifestations (hallucina-
tions and dysphoria). No other side effects required therapy. Of 
these 26 ADR requiring treatment, eight (31%) were rated as probably 
and 18 (69%) as possibly related to the study drugs. ADR that 
required either treatment or removal from the study contributed to 
54/174 (31%) of the total number of ADR. 
The time course of ADR is as follows: 32 ADR occurred during the 
observation period, 88 ADR at 24 hours, 41 at 48 hours and only 13 at 
72 hours. 
The total number of ADR was compared to the total number of 
doses and patient age with a Spearman Rank Correlation. Values of r 




Pain and Dose Analysis 
Interindividual variation of response to analgesics is prevalent 
in all postoperative pain studies. In a retrospective analysis 
Bellvllle and colleagues43 attempted to identify the source of such 
variation. Seven hundred and twelve patients were studied. Ten mg 
of morphine sulfate, 20 mg of pentazocine or both were administered 
for postoperative pain relief. Pain relief and patient characteris-
tics were compared. A highly significant correlation coefficient was 
shown between age and analgesia. In addition, more pain relief was 
observed with increasing age. Increased pain relief, in this study, 
was not associated with an increased Incidence of side effects. 
Therefore, the enhanced analgesia was not thought to be related to 
altered absorption or disposition, but rather due to pharmacodynamic 
changes. 
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Kaiko et al performed a double-blind crossover study using 8 
and 16 mg of morphine sulfate intramuscularly for 1104 doses in 715 
postoperative patients. The investigators rationalized these doses 
by claiming that they were used as the standard of comparison in the 
determination of the potency of investigational drugs which they had 
evaluated over a 20 year period. The patient response was assessed 
by comparisons of total pain relief scores (TOTPAR) observed between 
the age groups 18-29 and 70-89. In this study the aged patients 
responded to morphine as if they had received 3-4 times the dose 
received by the younger group. In addition to an increase in pain 
relief, an increase in duration of analgesic response was noted in 
the elderly patients. The correlation between age and analgesia was 
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much greater than any other correlation with analgesia including 
height, weight, body surface area, operative site, and initial pain 
intensity. The authors of this study suggested that age be used as 
the basis for determination of initial dosage for postoperative pain. 
Studies have shown increased*5, decreased46, and equivalent47 
pain sensitivity throughout life. Despite these varied results there 
is a generally accepted contention that a decrease in the information 
processing capacity of the central nervous system is a factor of 
48 
aging. However, changes in pain sensitivity may also be due to 
changing peripheral sensory organ function. There is some evidence 
that differences in tissue sensitivity to drugs becomes more pro-
nounced with age. These differences can be attributed to the physio-
logic or pathologic status of the tissues or systems involved such as 
the change in number of receptors or variation in the structural 
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features and integrity of the responsive tissue. 
Pain and its suppression are complex and subjective experiences. 
Age differences in pain thresholds may reflect changes in attitudinal 
prejudices or response bias rather than age differences in sensory 
and perceptual processes. Clark and Mehl5^ used shock intensity to 
measure pain response and concluded that perceptual or response 
biases interact with age. The elderly were inclined to label faint, 
vaguely noxious stimuli as non-noxious sensation while at higher 
levels of perceived pain intensity they are quite willing, signifi-
cantly more so than younger subjects, to label the stimulus as 
painful. 
The mean initial pain intensity (IPI) in the present study of 
3.1 implies that the average elderly patient ranked their initial 
pain intensity between the distressing and horrible categories. The 
numerical IPI of the elderly patients in this study is somewhat 
greater than the corresponding IPI findings in other postoperative 
pain studies. For example, in 150 postoperative patients 16% of whom 
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were over 60 years of age, Dobkin and colleagues noted the average 
IPI to be 2.9. However, the verbal pain intensity rating used in the 
later study had only four categories ranging from none (0) to severe 
pain (3). Therefore, the initial pain intensity in the elderly 
patients of the current study may actually be less than reported in 
other studies. 
Overall improvement in pain intensity was shown by the one hour 
and first dose values for SPID, SPAID, and TOTPAR. These results are 
expected from proven effective analgesics such as butorphanol and 
9 
morphine. Gilbert and colleagues also used summations of pain 
intensity difference to demonstrate the effectiveness of 2 mg of 
butorphanol for postoperative pain relief. In comparison to the mean 
SPID of 7.4 for the current study, Gilbert et al demonstrated a SPID 
of 6.7. However, the later study rated pain intensity on only a four 
point nominal scale rather than the six point McGill scale. There-
fore, the results of the current study do not demonstrate as great of 
a decrease in pain intensity as Gilbert's trial. This finding is 
probably attributed to the lower doses of butorphanol and morphine 
which have not been separated out at this analysis. 
Time to remedication in the current study was approximately 
three hours. This duration is similar to the usual dosing guidelines 
of butorphanol and morphine for remedication of every three to four 
hours. It is unclear if the shorter durations, those less than three 
hours, were due to one drug or the other or possibly due to the lower 
dosages of the two study drugs (butorphanol 1 mg and morphine 4 mg). 
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As mentioned previously, Pachter and Evans noted that the duration 
of analgesia is influenced by the dose, patient size, pain threshold, 
environmental influences, and the severity and persistence of the 
pain stimulus. In younger subjects, pain relief persisted for 
approximately two hours with low doses of butorphanol (0,5 mg - 1 mg) 
and three to four hours with higher doses (2-4 mg) . In a double-
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blinded post-surgical pain study, Lippman et al made this same 
association for low doses of morphine. He concluded that low doses 
had a shorter time until remedication than did larger doses. 
In the present study, when patients were separated into surgical 
categories, the mean initial pain intensities were quite similar 
ranging from 3.0 to 3.7. The time between the first and second dose 
differed among groups. The time to remedication was the shortest for 
the total knee arthroplasty (TKA) patients with a mean of 1.6 hours 
compared to the mean of 3.3 hours for the other surgical procedures. 
Also the mean SPID and TOTPAR for patients with total knee surgery 
for the first dose was -0.07 and 4.3 respectively, compared with the 
SPID and TOTPAR in the remainder of patients of 8.9 and 10,7. 
Although the numbers of patients are small, these data may lead to 
the conclusion that increased doses or more frequent dosing of anal-
gesics for TKA patients may be warranted and should be Investigated 
further. 
The total number of doses averaged 10.5 for the 72 hour study 
period which requires some interpretation since seven patients were 
withdrawn from the study before the 72 hour period was completed. 
Also three patients required analgesia only in the immediate post-
operative period. However, there was a general trend for patients to 
be taking fewer doses and/or waiting longer between doses as the 
postoperative period progressed. These findings may empirically be 
anticipated in acute pain control. 
Although Kaiko51 and Bellville et al43 concluded that the 
elderly may experience longer pain relief from narcotic analgesics, 
the preliminary data of the present study suggest that the elderly 
respond very similarly to the general population. For example, 
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Communale and Filtzer studied meperidine and butorphanol in 91 
postoperative patients with moderate to severe pain. The mean ages 
for the butorphanol and meperidine groups were 42.1 and 46.5 years, 
respectively. Analgesia was comparable between groups and the mean 
duration between doses was between four and five hours for both 
4 
drugs. Lippman and colleagues also compared butorphanol and mor-
phine in 100 postoperative patients with moderate to severe pain in a 
double-blind randomized trial. The mean age of the study partici-
pants was 38 years ranging from 16 to 74 years. In this study, 1 mg 
of butorphanol and 5 mg of morphine had a mean duration of analgesia 
9 
of approximately 1.5 hours. Gilbert and colleagues compared 
pentazocine 30 and 60 mg with butorphanol 1, 2, and 4 mg in 124 post-
operative patients. The subject's ages ranged from 23-98 years. In 
this trial the majority of subjects required remedication during the 
2-4 hour period after the initial dose despite which drug they had 
received. All three of these studies claimed effective analgesia. 
51 43 Both studies by Kaiko et al and Bellville et al demonstrated 
longer times before redosing, but both trials used larger doses of 
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analgesics than the current study. Kaiko et al used 8 and 16 mg of 
morphine and Bellville et al used 10 mg of morphine. Despite this 
difference, both studies did use subjects experiencing postoperative 
pain. These inconsistent findings may simply reiterate the common 
knowledge that the analgesic dosage must be titrated to an individual 
patient's needs regardless of age, and that duration of effect is 
more related to dose than age. 
In any pain study the validity of the scales used to assess pain 
must be addressed. Pain is difficult to measure due to its complex 
and highly subjective nature. The verbal descriptor scale used to 
assess pain Intensity was the Present Pain Intensity Scale taken from 
38 
the McGill Pain Questionnaire. The words used in this scale were 
studied and found to be the most uniform terms for each level of 
pain. This scale gives ordinal data because the exact distance 
between categories cannot be assumed to be equal. The advantages of 
a verbal scale of this type is that it is short, easily completed, 
and well understood. The disadvantage is that the scale artificially 
superimposes quantum changes in pain rather than graduated ones. 
The Visual Analogue Scale (VAS) consists of a 10 centimeter line 
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labeled with the extremes of pain on each end. Sriwatanakul et al 
compared many configurations of the VAS and found the linear-
horizontal scale to be the most reliable and preferred by partici-
pants. The advantages of this instrument are that it is sensitive to 
minute changes in pain and provides interval data. The most impor-
tant limitation is that postoperative patients occasionally find it 
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difficult to report their pain on this scale. ' In the present 
study the elderly experienced difficulty in completing the VAS 
because of sedation or visual problems. Sedation and blurred vision 
are common sequelae of anesthetics. Therefore, the VAS may not be an 
effective tool for pain differentiation in postoperative patients. 
When both scales are used the advantages are increased and the 
limitations lessened. Correlations between the parameters derived 
from the various scales were calculated. The r value quanitates the 
relationship between the mutually independent variables. An r value 
of +1 shows an exact linear correlation whereas a value of -1 shows 
an exact inverse correlation. A Spearman Rank Correlation was used 
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due to the population size and ordinal nature of the data. The 
correlation between SPID and SPAID was reasonable (r= + 0.77). SPAID 
vs TOTPAR and SPID vs TOTPAR were similarly correlated with r values 
of 0.71 and 0,82, respectively. These correlations may have been 
greater with an increased patient population. For example, Littman 
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et al utilized information from 1493 participants and found 
correlations between SPID versus SPAID, SPID versus TOTPAR and SPAID 
versus TOTPAR of 0.93, 0.91 and .90, respectively. Despite the much 
smaller patient number in this study, a stronger correlation would be 
expected due to the more homogenous study population and study 
design. Possibly the lower correlation is a factor of patient age. 
The elderly may not have personally identified with words such as 
horrible or excruciating, yet marked the VAS very high. Also Littman 
et al utilized a mixed population of acute and chronic pain patients. 
It is possible that the correlations utilizing data from only the 
postoperative patient may have produced r values similar to the 
present investigation. 
Vital Sign Assessment 
Vital sign assessment was compared per observation interval to 
ascertain if there was a specific time period in which the maximum 
change occurred for a certain measurement. This information could be 
utilized to enhance the efficacy and efficiency of clinical monitor-
ing, A trend was evident for the initial two hours of observation. 
During this period 33/40 patients experienced the greatest change In 
blood pressure and respirations. Twenty-nine of 40 patients experi-
enced the maximal change in pulse and oxygen saturation also in this 
time frame. Therefore, it appears the initial two hours after a dose 
of narcotic analgesic is the most critical time to assess vital sign 
changes. 
Vital sign changes observed in the current study were either 
clinically insignificant or related to other phenomena as noted in 
the results section. These findings agree with those of other 
investigators. For instance, Ameer and Salter1^ reviewed 19 clinical 
trials using parenteral butorphanol and summarized that in most 
double-blind short-term clinical trials, vital signs were not 
18 
appreciably changed. Popio et al compared the hemodynamic and 
respiratory effects of morphine and butorphanol in patients under-
going cardiac catheterization. They demonstrated no significant 
difference in either the morphine or the butorphanol group for 
respiratory rate, pO^ or heart rate. However, morphine produces 
peripheral dilitation of both arteries and veins resulting in venous 
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pooling and hypotension. The hypotension is usually orthostatic in 
nature. Therefore, it is not unexpected that hypotension was unusual 
in our postoperative patients who remained at bed rest during the 
initial observation period. 
Adverse Drug Reaction Assessment 
The sedation ratings showed an average increase in sedation over 
time with a mean of -1.28 at one hour and a summation difference of 
-3.57 for the first dose. This is certainly an expected result with 
both of these drugs and in postanesthesia patients. Unfortunately it 
is impossible to assess whether the higher doses or one drug produced 
more sedation. It is also difficult to assess what percentage of the 
sedation was related to the anesthetic or simply the stress of 
surgery itself. Since a baseline sedation reading was taken prior to 
dosing, the other factors are somewhat corrected but cannot be 
nullified. Overall an increase in sedation was observed in 65% of 
15 
patients. Pachter and Evans state that 1-2 mg of butorphanol would 
4 
cause sedation in 10-25% of patients. Lippman et al showed similar 
incidences of sedation between morphine sulfate and butorphanol of 81 
and 89%, respectively. As in the current study, the population in 
the later study was postoperative and the higher incidence of sedation 
could probably be attributed to residual effects of the anesthetic. 
Many patients experienced adverse drug reactions (ADR) during 
the current study. However, when these were assessed for probability 
of causal relationship to the study drug by the algorithm developed 
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by Hutchinson et al the number of ADR compared to the original 
assessment dropped considerably. One hundred and seventy-four ADR 
were assessed. One ADR could be assessed as many as four times if 
the patient experienced the side effect during the observation 
period, at 24 hours, 48 hours, and at 72 hours. The algorithm may 
29 
vary between investigators but its reliability and validity have been 
demonstrated 
The occurrence of 174 ADR in 40 patients makes the incidence of 
ADR seem very high, but all ADR were considered in the algorithm 
including relatively minor side effects such as pruritus, dry mouth 
and headache. Therefore, the more clinically relevant results relate 
to the following two questions: 1) how many patients are removed 
from the study due to adverse reactions; and 2) how many of the ADR 
required treatment? Thirty-one percent of all ADR required treatment 
or resulted in the withdrawal of the patient from the study. Leach 
23 
and Roy studied 152 patients with an average age of 78.3 years on 
an acute geriatric until and all ADR were monitored. They found 117 
adverse reactions in 94 patients representing an ADR occurrence rate 
of 18.8%. In their study diamorphine and insulin had the highest 
adverse reaction rates. Leach and Roy also assessed the ADR causal-
ity by the Hutchinson algorithm and presented results similar to the 
present study. Only 2.5% of the ADR were deemed unlikely. Five 
percent of the 117 ADR were assessed to be definitely related to the 
drug in question. The remainder were probable or possible and 
constituted 92.51. Therefore, it appears that geriatric patients are 
a high risk group for ADR and are more sensitive to certain drugs 
such as narcotic analgesics. The concomitant use of many different 
drugs and the resultant drug interactions, two parameters not assess-
ed in the current trial, may also contribute to the higher incidence 
of ADR in the elderly. 
The number of ADR in this study showed little correlation with 
age in contrast to results from other investigators such as Leach and 
30 
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Roy aod Hurwitz . Three explanations for this inconsistency may 
be offered: 1) only 10% of the population in the current study was 
greater than 80 years of age; 2) the present study population may be 
too homogenous not allowing a correlation to be observed even if 
present; and 3) the sample size may be too small to render such 
correlations. The other studies cited reviewed 1268 and 521 
patients, respectively. 
The correlation between ADR and total doses was also not signif-
icant. This could be due to the fact that some ADR such as nausea, 
vomiting, pruritus are not dose-related whereas sedation, respiratory 
depression, and central nervous system effects are more likely to be 
observed with higher doses. In contrast, a stronger correlation 
might be expected in elderly patients due to their altered elimina-
51 37 tion of morphine and butorphanol 
It is interesting to at least mention the time course of occur-
rence of ADR since many pain studies focus only on single dose and 
the ADR resulting from that brief observation period. The findings 
of the current study indicate that only 31/174 ADR occurred during 
the observation phase. The lower Incidence of ADR in single-dose 
studies may therefore be less applicable to true clinical usage since 
it is rare when a patient receives just one dose of a narcotic 
analgesic. 
CONCLUSION 
Analysis of the data from this study did tend to support pre-
viously reported findings of increased sensitivity of elderly 
patients to adverse reactions. It can also be concluded that 
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individual responses vary widely and may not be readily predictable 
by demographic and health history data alone. This would reinforce 
the clinical dictum that dosage titration, caution and close observa-
tion should be used when administering opioids to this population. 
It is not yet possible to draw comparative conclusions about 
butorphanol versus morphine from this still blinded study. When the 
code is broken it will be worthwhile to note whether differences 
exist in terms of dose-response for pain relief, duration between 
doses, and adverse drug reactions. The question that remains to be 
answered is whether the agonist/antagonist agent, butorphanol tar-
trate, has specific advantages compared to morphine sulfate in 
elderly patients for postoperative pain. 
TABLES 
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TABLE 1. PATIENT DEMOGRAPHICS, SURGERY TYPE AND ANESTHETIC CHOICE 
Patient # Age Gender Surgery Anesthetic 
(years) 
1 65 F Total knee arthroplasty 1,2 
2 60 F Total knee arthroplasty 1 
3 65 F Total hip arthroplasty 1,3 
4 67 F CMCA 1,3 
5 62 M Colectomy 1 
6 85 F TAH/BSO 1,2,3 
7 71 M Total hip arthroplasty 1.2,3 
8 66 F BSO, ilieum dissection 1,3 
9 69 H Hernia repair 0 
10 64 M Colectomy 1 
11 64 F TAH/BSO 1,2 
12 71 M Colectomy 1,2 
13 78 F Total hip arthroplasty 1,2,3 
14 66 M Colectomy 1,2,3 
15 80 F Varicose vein ligation 1,3 
16 70 F Parathyroid excision 1,2,3 
17 62 F TAH/BSO 1,2 
18 78 F Total knee arthroplasty 1,2 
19 71 M Laminectomy 1,3 





M = Male 
F = Female 
CMCA = carpal metacarpal arthroplasty 
L3 = third lumbar vertebrae 
TAH = total abdominal hysterectomy 
TVH = total vaginal hysterectomy 
BSO » bilateral salpingo oophorectomy 
TURP = transurethral resection of the prostate 
0 = neither ^ 
1 - isoflurane (Forane ) 
2 = fentanyl 
3 = nitrous oxide 
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TABLE 1. PATIENT DEMOGRAPHICS, SURGERY TYPE AND ANESTHETIC CHOICE 
(continued) 
Patient # Age Gender Surgery Anesthetic 
(years) 
21 85 F TAH/BSO 1,2,3 
22 60 M Colectomy 2,3 
23 73 M Laminectomy 113 
24 75 M TURP/vasectomy 0 
25 66 F Total knee arthroplasty 3 
26 74 F Total hip arthroplasty 1 
27 63 F Colectomy 1,2 
28 71 M Hemithyroidectomy 1 j 2} 3 
29 61 M Total hip arthroplasty 1,3 
30 60 M Partial mandibulectomy 1 9 2 £ 3 
31 61 F Stamey procedure 1,2,3 
32 67 F Total hip arthroplasty 1,3 
33 70 M Tarsal arthroplasty 2 
34 66 M Total knee arthroplasty 2,3 
35 63 M Total knee arthroplasty 3 
36 87 F Wide excision neck 1,2,3 
37 67 F Total knee arthroplasty 2 ,3 
38 77 F Laminectomy 3. j 2 j 3 
39 70 F Laminectomy 1 j 2 j 3 





M = Male 
F = Female 
CMCA = carpal metacarpal arthroplasty 
L3 = third lumbar vertebrae 
TAH = total abdominal hysterectomy 
TVH = total vaginal hysterectomy 
BSO = bilateral salpingo oophorectomy 
TURP = transurethral resection of the prostate 
0 = neither 
1 = isoflurane (Forane ) 
2 = fentanyl 
3 = nitrous oxide 
TABLE 2. PATIENT SPECIFIC PAIN INTENSITY, PAIN RELIEF 



















1 0.5 0.5 14.0 14.0 -0.5 - 0.5 2.50 1.00 
2 0 - 6.0 - 2.0 -26.0 2.0 0 1.00 3.00 
3 0.5 0.5 - 0.5 13.5 1.5 1.5 -1.75 1.25 
4 3.5 3.5 68.5 62.5 4.0 6.0 -1.80 2.95 
5 2.5 2.5 * * 4.0 8.0 0 0 
6 1.5 - 1.0 13.0 -9.0 3.0 0 -1.75 - 2.25 
7 1.5 3.5 22.5 60.5 1.5 1.5 0.62 - 4.10 
8 3.0 3.0 * * 4.5 4.5 0.38 0.25 
9 1.5 1.5 15.0 15.0 2.0 2.0 -0.13 - 0.50 
10 0.5 0.5 39.0 39.0 2.0 2.0 -0.63 - 2.00 
11 2.5 6.5 36.0 154.0 1.0 8.0 -0.13 - 0.25 
12 2.0 2.0 52.0 52.0 2.5 2.5 0.13 0.13 
13 3.0 11.0 21.5 44.5 4.5 19.5 -3.50 -10.50 
14 0.5 0.5 10.0 10.0 2.5 2.5 -3.50 - 3.50 
15 1.5 26.5 15.0 450.5 3.0 46.0 0 i 0 
16 3.5 23.5 45.0 284.0 5.0 33.0 -1.50 -15.50 
17 1.5 1.5 43.0 41.0 2.5 2.5 -2.75 - 3.50 
18 0.5 0.5 - 1.0 - 1.0 1.5 1.5 0 0 
19 2.5 12.5 48.5 257.5 3.0 13.0 0 - 7.98 
20 1.5 0.5 12.5 12.5 0 0 0.19 0.19 
ABBREVIATIONS 
1 hr • calculations for one hour after the initial dose 
first = calculations for first dose 
SPID = summation of pain intensity differences 
SPAID = summation of pain analog intensity differences 
TOTPAR = total pain relief summation 
SSED = summation of sedation differences 
* = data not available 
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TABLE 2. PATIENT SPECIFIC PAIN INTENSITY, PAIN RELIEF 
AND SEDATION SUMMATIONS (continued) 















21 1.5 - 4.5 19.5 20.5 * 1.0 -3.50 - 7.50 
22 1.5 1.5 28.0 28.0 2.5 4.5 -0.88 0.25 
23 0 0 -14.0 - 14.0 - 0.5 - 0.5 0 0 
24 0.5 2 • 5 42.0 83.0 1.5 5.5 -3.75 0 
25 1.5 1.5 29.0 29.0 1.5 1.5 0 0 
26 3.0 10.0 55.0 169.0 4.0 16.0 -0.75 - 0.75 
27 3.0 37.0 * * 1.5 40.5 -2.50 -23.50 
28 5.5 11.5 57.0 - 91.0 6.0 20.0 -0.25 - 2.25 
29 2.5 20.5 44.0 44.0 3.0 21.0 -2.00 -20.00 
30 0.5 0.5 06.0 6.0 0.5 0.5 0 0 
31 3.8 76.8 106.5 1682.5 84.5 84.5 -3.75 21.75 
32 0 0 -1.5 -1.0 0 0 -1.00 - 1.00 
33 3.0 7.0 63.0 147.0 3.0 7.0 -1.75 - 3.75 
34 1.0 1.0 54.0 41.0 3*5 11.5 -5.25 -12.00 
35 1.5 1.5 21.5 71.5 3.0 13.0 -3.25 -18,25 
36 1.5 19.5 19.5 155.7 * * -1.00 -20.00 
37 0.5 0.5 15.0 15.0 3.0 3.0 -1.75 - 1.75 
38 1.5 1.5 -1.5 -1.0 1.5 1.5 -4.50 - 4.50 
39 1.5 6.5 27.0 442.0 3.5 30.5 -0.25 - 6.25 
40 -2.5 6.5 -41.0 283.0 1.5 26.5 -2.00 - 2.00 
mean 1.6 7.3 25.0 123.9 4.5 11.6 -1.59 - 3.57 
standard 
deviation 1.4 14.3 26.6 290.1 13.4 16.8 2.49 7.9 
ABBREVIATIONS 
1 hr = calculations for one hour after the initial dose 
first = calculations for first dose 
SPID = summation of pain intensity differences 
SPAID = summation of pain analog intensity differences 
TOTPAR = total pain relief summation 
SSED = summation of sedation differences 
* = data not available 
TABLE 3. DOSES AND MILLILITERS OF STUDY DRUG BY PATIENT 
observation 24 hour 48 hour 72 hour total total 
Pt # doses mis doses mis doses mis doses mis doses mis 
1 2 1.50 6 6.00 4 4.75 4 3.50 17 16.00 
2 2 1.50 WD WD WD WD WD WD 2 2.00 
3 3 2.00 4 3.50 4 3.50 1 1,00 14 11,00 
4 2 2.00 7 7.00 4 3.50 ND ND 13 12 • 5 0 
5 2 2.00 2 2.00 WD WD WD WD 4 4.00 
6 2 1.75 1 0.75 ND ND ND ND 4 3.25 
7 2 2.00 8 7.50 6 6.00 5 4.50 21 19.50 
8 2 2.00 3 3.00 2 2.00 2 2.00 9 9.00 
9 2 2.00 2 1.00 1 0.50 ND ND 5 3.25 
10 3 2.75 6 5.50 3 2.50 ND ND 13 10,75 
11 2 1.75 2 1.50 ND ND ND ND 4 3.25 
12 2 2.00 5 5.00 6 6.00 4 4.00 18 18.00 
13 2 1.50 1 1.00 5 2.50 3 1.50 11 6.50 
14 2 2.00 WD WD WD WD WD WD 1 1.00 
15 1 1.00 2 2.00 2 2.00 ND ND 5 5.00 
16 1 1.00 ND ND ND ND ND ND 1 1.00 
17 2 1.75 3 2,25 1 0.50 ND 8.00 7 5.25 
18 3 3.00 7 7.00 4 4.00 3 3.00 17 17.00 
19 2 2.00 5 4.75 5 5.00 6 6.00 18 17.75 
20 4 4.00 5 5.00 4 4.00 ND ND 13 13.00 
ABBREVIATIONS 
pt # = patient study number 
mis = milliliters of study drug 
WD = patient was withdrawn from the study 
ND = no drug administered to the patient 
TABLE 3. DOSES AND MILLILITERS OF STUDY DRUG BY PATIENT 
(continued) 
observation 24 hour 48 hour 72 hour total total 
>t # doses mis doses mis doses mis doses mis doses mis 
21 2 1.50 3 1.50 WD WD WD m 5 3.00 
22 2 1.75 5 4.50 4 3.75 WD WD 11 10.00 
23 3 3.00 7 7.00 7 5.50 4 4.00 21 19.50 
24 2 1.70 1 0.75 ND ND ND ND 3 2.50 
25 2 2.00 3 3.00 3 3.00 2 2.00 10 10.00 
26 2 1.50 6 3.50 3 3.00 2 1.00 11 9.00 
27 1 1.00 4 1.13 4 2.00 6 3.00 15 7.13 
28 2 2.00 ND ND ND ND ND ND 2 2.00 
29 2 2.00 2 1.00 ND ND ND ND 4 3.00 
30 3 3.00 6 5.00 5 5.00 ND ND 14 13.00 
31 1 1.00 5 5.00 4 3.50 ND ND 10 9.00 
32 3 3.00 6 6.00 WD WD WD WD 9 9.00 
33 3 3.00 6 6.00 WD WD WD WD 24 24.00 
34 2 2.00 6 6.00 3 3.00 4 4.00 16 16.00 
35 2 2.00 ND ND ND ND ND ND 2 2.00 
36 1 1.00 2 1.50 1 1.00 ND ND 4 3.00 
37 3 2.50 8 8.50 5 8.50 5 5.00 22 24.50 
38 3 3.00 6 6.00 6 6.00 6 6.00 21 21.00 
39 1 1.00 1 0.50 ND ND ND ND 2 1.50 
40 2 2.00 3 3.00 1 0.50 WD WD 5 4.50 
ABBREVIATIONS 
pt # = patient study number 
mis » milliliters of study drug 
WD = patient was withdrawn from the study 
ND = no drug administered to the patient 
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TABLE 4. PATIENTS GROUPED BY SURGERY 
Patient # Surgery IPI time total mis 
5 Colectomy 3 2.25 4 4.0 
10 Colectomy 3 1.25 13 10.5 
12 Colectomy 5 1.08 18 18.0 
14 Colectomy 4 1.08 11 9.5 
22 Colectomy 3 2.17 11 10.0 
27 Colectomy 4 6.08 15 7.1 
19 Laminectomy 4 3.66 18 17.7 
23 Laminectomy 3 1.25 21 19.5 
38 Laminectomy 5 1.25 21 21.0 
39 Laminectomy 2 7.83 2 1.5 
11 TAH/BSO 4 2.17 4 3.3 
17 TAH/BSO 3 1.20 7 5.3 
21 TAH/BSO 2 2.83 5 3.0 
3 Total hip arthroplasty 4 2.25 14 11.0 
7 Total hip arthroplasty 4 2.41 21 19.5 
13 Total hip arthroplasty 3 3.33 11 6.5 
26 Total hip arthroplasty 3 3.00 11 9.0 
29 Total hip arthroplasty 3 4.92 4 3.0 
32 Total hip arthroplasty 4 1.00 9 9.0 
40 Total hip arthroplasty 2 5.45 4 3.5 
1 Total knee arthroplasty 4 1.00 17 16.0 
2 Total knee arthroplasty 2 1.83 1 1.0 
18 Total knee arthroplasty 5 1.00 17 17.0 
25 Total knee arthroplasty 4 1.16 10 10.0 
34 Total knee arthroplasty 3 2.17 16 16.0 
35 Total knee arthroplasty 2 3.00 2 2.0 
37 Total knee arthroplasty 4 1.30 22 24.5 
ABBREVIATIONS 
IPI = initial pain intensity 
tine = hours until remedication 
total = total doses 
mis = total milliliters 
TAH = total abdominal hysterectomy 
BSO = bilateral salpingo oophorectomy 
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TABLE . GREATEST CHANGE IN RESS BY PATIENT 
DURING THE OBSERVATION PERIOD 
Patient # BP 1 BP 2 Time inl 
1 150/80 134/70 1 
2 123/63 104/66 1 
4 106/60 110/70 1 
8 112/70 100/60 1 
22 160/104 140/96 1 
29 118/64 100/50 1 
32 138/90 144/88 1 
33 122/82 150/84 1 
9 125/95 110/80 2 
18 148/86 134/80 2 
21 122/60 128/64 2 
24 140/80 136/76 2 
36 184/82 152/90 2 
5 172/96 148/78 3 
7 120/80 110/78 3 
11 182/96 164/80 3 
13 94/52 108/60 3 
16 150/80 156/90 3 
19 102/56 128/50 3 
20 112/70 120/80 3 
ABBREVIATIONS 
BP 1 = first reading of greatest blood pressure change (mmHg) 
BP 2 = second reading of greatest blood pressure change (mmHg) 
Time intervals 
1 = 0 to 15 minutes 
2 = 15 to 30 minutes 
3 = 30 minutes to 1 hour 
4 = 1 to 2 hours 
5 = 2 to 3 hours 
6 = 3 to 4 hours 
8 = 5 to 6 hours 
TABLE 5. GREATEST CHANGES IN BLOOD PRESSURE BY PATIENT 
DURING THE OBSERVATION PERIOD (continued) 
Patient # BP 1 BP 2 Time int 
23 164/76 128/70 3 
30 152/102 190/104 3 
35 160/80 152/80 3 
39 139/56 112/50 3 
3 95/55 110/65 4 
6 155/80 150/72 4 
10 140/90 155/92 4 
14 156/85 168/92 4 
17 104/70 128/72 4 
26 110/70 132/80 4 
37 132/78 110/74 4 
38 136/66 154/74 4 
40 125/80 85/55 4 
12 142/76 122/76 5 
25 102/70 92/70 5 
27 140/78 122/64 5 
28 138/84 142/82 5 
15 120/86 176/100 6 
34 160/84 140/78 6 
31 110/54 120/70 8 
ABBREVIATIONS 
BP 1 = first reading of greatest blood pressure change (mmHg) 
BP 2 = second reading of greatest blood pressure change (mmHg) 
Time intervals 
1 = 0 to 15 minutes 
2 = 15 to 30 minutes 
3 = 30 minutes to 1 hour 
4 = 1 to 2 hours 
5 = 2 to 3 hours 
6 = 3 to 4 hours 
8 = 5 to 6 hours 
TABLE 6. GREATEST CHANGE IN RESPIRATIONS BY PATIENT 
DURING THE OBSERVATION PERIOD 
Patient it Respirations 1 Respirations 2 Time Interval 
4 20 12 1 
32 18 14 1 
33 16 12 1 
9 20 16 1 
24 16 12 1 
11 24 20 1 
13 14 16 1 
35 20 12 1 
17 16 12 1 
6 20 15 1 
1 16 13 2 
2 20 15 2 
8 14 24 2 
18 20 16 2 
21 16 14 2 
37 12 20 2 
3 10 11 2 
38 20 24 2 
28 18 12 2 
34 16 20 2 
ABBREVIATIONS , Ri^pTrationT-! = first reading greatest respiration change 
(breaths/minute) 
Respirations 2 = second reading greatest respiration change 
(breaths/minute) 
Time intervals 
1 = 0 to 15 minutes 
2 = 15 to 30 minutes 
3 = 30 minutes to 1 hour 
4 = 1 to 2 hours 
5 = 2 to 3 hours 
6 = 3 to 4 hours 
NC = No change 
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TABLE 6. GREATEST CHANGE IN RESPIRATIONS BY PATIENT 
DURING THE OBSERVATION PERIOD (continued) 
Patient f Respirations I Respirations 2 Time Interval 
20 18 24 3 
7 16 10 3 
23 18 16 3 
30 22 30 3 
39 20 16 3 
25 16 10 3 
15 10 18 3 
5 24 20 4 
19 18 12 4 
10 19 11 4 
26 16 12 4 
12 20 14 4 
27 20 14 4 
16 18 14 5 
14 20 18 5 
31 16 20 5 
29 16 20 6 
22 20 16 6 
36 NC NC NC 
40 NC NC NC 
ABBREVIATIONS 
Respirations 1 = first reading greatest respiration change 
(breaths/minute) 
Respirations 2 = second reading greatest respiration change 
(breaths/minute) 
Time intervals 
1 = 0 to 15 minutes 
2 = 15 to 30 minutes 
3 = 30 minutes to 1 hour 
4 = 1 to 2 hours 
5 = 2 to 3 hours 
6 = 3 to 4 hours 
NC = No change 
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TABLE . GREATEST CHANGE IN P S BY PATIENT 
DURING THE OBSERVATION PERIOD 
Patient # Pulse 1 Pulse 2 Time interval 
1 96 84 1 
2 80 76 1 
4 95 88 1 
9 72 69 1 
10 80 83 1 
11 90 100 1 
13 110 80 1 
16 63 68 1 
18 71 76 1 
20 94 100 1 
31 72 98 1 
35 90 83 1 
7 84 77 2 
17 54 60 2 
23 64 74 2 
25 98 92 2 
26 65 76 2 
32 76 82 2 
37 99 104 2 
29 90 85 3 
ABBREVIATIONS 
Pulse 1 = first reading of pulse greatest change (beats/minute) 
Pulse 2 = second reading of pulse greatest change (beast/minute) 
Time intervals 
1 = 0 to 15 minutes 
2 = 15 to 30 minutes 
3 = 30 minutes to 1 hour 
4 = 1 to 2 hours 
5 = 2 to 3 hours 
6 = 3 to 4 hours 
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TABLE . GREATEST CHANGE IN P S BY PATIENT 
DURING THE OBSERVATION PERIOD (continued) 
Patient # Pulse 1 Pulse 2 Time interval 
30 76 84 3 
36 60 76 3 
39 75 67 3 
5 120 103 4 
12 104 112 4 
14 87 94 4 
22 100 106 4 
27 92 100 4 
33 68 58 4 
3 72 96 5 
6 76 66 5 
15 69 90 5 
34 107 113 5 
40 84 78 5 
8 75 67 6 
19 69 76 6 
21 68 77 6 
24 60 68 6 
28 71 77 6 
38 90 98 6 
ABBREVIATIONS 
Pulse 1 = first reading of pulse greatest change (beats/minute) 
Pulse 2 = second reading of pulse greatest change (beast/minute) 
Time intervals 
1 = 0 to 15 minutes 
2 = 15 to 30 minutes 
3 = 30 minutes to 1 hour 
4 = 1 to 2 hours 
5 = 2 to 3 hours 
6 « 3 to 4 hours 
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TABLE . GREATEST CHANGE BY PATIENT 
DURING THE OBSERVATION PERIOD 
Patient # OX 1 OX 2 Time interval 
4 100 90 1 
32 94 91 1 
33 94 92 1 
1 92 90 1 
8 96 94 1 
29 90 84 1 
9 89 93 1 
24 93 92 1 
39 98 89 1 
10 93 94 1 
14 100 98 1 
31 95 91 1 
2 95 90 2 
11 95 92 2 
5 95 97 2 
37 100 98 2 
18 100 96 3 
13 90 87 3 
20 89 91 3 
7 94 96 3 
ABBREVIATIONS 
OX 1 = first reading of greatest oximetry change (% saturation) 
OX 2 = second reading of greatest oximetry change (% saturation) 
Time intervals 
1 = 0 to 15 minutes 
2 = 15 to 30 minutes 
3 - 30 minutes to 1 hour 
4 « 1 to 2 hours 
5 = 2 to 3 hours 
6 = 3 to 4 hours 
7 = 4 to 5 hours 
* = no reading available 
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TABLE . GREATEST CHANGE BY PATIENT 
DURING THE OBSERVATION PERIOD (continued) 
Patient # OX 1 OX 2 Time Interval 
15 91 98 3 
22 98 96 4 
21 91 94 4 
35 93 83 4 
16 89 94 4 
17 92 96 4 
3 85 97 4 
12 93 91 4 
34 88 93 4 
30 89 86 5 
26 96 99 5 
28 88 91 5 
25 100 98 5 
27 93 91 5 
23 87 95 6 
19 82 91 6 
6 89 84 7 
36 * * * 
38 * * * 
40 * * * 
ABBREVIATIONS 
OX I = first reading of greatest oximetry change (% saturation) 
OX 2 = second reading of greatest oximetry change (% saturation) 
Time intervals 
1 = 0 to 15 minutes 
2 = 15 to 30 minutes 
3 = 30 minutes to 1 hour 
4 = 1 to 2 hours 
5 = 2 to 3 hours 
6 = 3 to 4 hours 
7 = 4 to 5 hours 
* = no reading available 
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TABLE 9. ADVERSE DRUG REACTIONS A D PROBABILITY ASSESSMENT 
DURING THE OBSERVATION AND 24 HOUR PERIODS 
Observation Probability 24 hour Probability 
Patient # ADR of ADR ADR of ADR 
1 nausea 3 nausea 2 
2 pruritus 3 pruritus _4 
3 nausea -1 dysphoria 2 
4 cold -2 nausea 1 
vertigo 1 
cold -2 
5 XS sedation 5 XS sedation 5 
6 none none 
7 none none 
8 none pruritus 3 
9 none nausea 1 
10 diaphoresis 2 none 
11 none none 
12 nausea 4 bad dreams 3 
13 nausea 4 
vision prbs 4 vision prbs 4 
14 none WD 
15 vision change 2 nausea 3 
headache -1 lethargic 2 




Patient # = patient study number 
ADR = adverse drug reaction 
XS = excessive 
none = no side effects 
prbs = problems 
WD = patient was withdrawn from study 
Probability that study drug 




< 0 unlikely 
Scores from algorithm-Hutchinson TA et al. JAMA 1979;242(7):633-638. 
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TABLE 9. ADVERSE DRUG REACTIONS AID PROBABILITY ASSESSMENT 










17 none 0 dry mouth -1 
18 nausea 0 nausea 2 
vomiting 0 vomiting 2 
dry mouth 0 pruritus 3 
insomnia -2 
dry mouth 0 
19 none diaphoresis 2 
dry mouth 3 
insomnia -1 
20 nausea 1 nausea 4 
vertigo 3 
21 nausea 1 agitation 5 
dysphoria 5 
22 confusion 5 headache 3 
vertigo 1 
bad dreams 4 
confusion 5 
23 vertigo -1 bad dreams 4 
eye changes -2 vertigo 1 
24 none dry mouth 1 
nausea 4 




Patient # = patient study number 
ADR = adverse drug reaction 
XS = excessive 
none = no side effects 
prbs = problems 
WD = patient was withdrawn from study 
Probability that study drug 




< 0 unlikely 
Scores from algorithm-Hutchinson TA et al. JAMA 1979;242(7):633-638. 
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TABLE 9. ADVERSE DRUG REACTIONS AD PROBABILITY ASSESSMENT 
DURING THE OBSERVATION AND 24 HOUR PERIODS (continued) 
Observation Probability 24 hour Probability 
Patient # ADR of ADR ADR of ADR 
26 nausea 0 vomiting 3 




dry mouth 1 
27 none none 
28 none dry mouth 1 
insomnia 0 
29 nausea 0 nausea 0 
vomiting 0 vomiting 0 
vertigo 3 
insomnia -2 
dry mouth 1 





31 nausea -1 tinnitus -2 
dry mouth 0 




dry mouth 1 
palpitations 1 
ABBREVIATIONS 
Patient // = patient study number 
ADR = adverse drug reaction 
XS = excessive 
none = no side effects 
prbs = problems 
WD = patient was withdrawn from study 
Probability that study drug 




< 0 unlikely 
Scores from algorithm-Hutchinson TA et al. JAMA 1979;242(7):633-638 
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TABLE 9. ADVERSE DRUG REACTIONS A D PROBABILITY ASSESSMENT 
DURING THE OBSERVATION AND 24 HOUR PERIODS (continued) 
Observation Probability 24 hour Probability 
Patient # ADR of ADR ADR of ADR 
33 none flushing 2 
vertigo 5 
dry mouth 5 
34 nausea 4 nausea 4 




dry mouth 3 
35 none insomnia -1 
dry mouth 2 
36 dry mouth 2 nausea 4 
dry mouth 3 
37 none vertigo 3 
38 none nausea 4 
dry mouth 3 
39 nausea 1 nausea 3 
vomiting 1 vomiting 3 
dry mouth 1 
40 none nausea 4 
confusion 4 
illusions 4 
dry mouth 3 
ABBREVIATIONS 
Patient # = patient study number 
ADR = adverse drug reaction 
XS = excessive 
none = no side effects 
prbs = problems 
WD - patient was withdrawn from study 
Probability that study drug 




< 0 unlikely 
Scores from algorithm-Hutchinson TA et al. JAMA 1979;242(7):633-638. 
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TABLE 10 ADVERSE DRUG REACTIONS AND PROBABILITY ASSESSMENT 
DURING THE 48 AND 72 HOUR PERIODS 
Patient # 48 hour ' Probability 72 hour Probability 
ADR of ADR ADR of ADR 
1 pruritus 2 none 
2 WD WD 
3 none none 
4 none none 
5 WD WD 
6 nausea 1 none 
7 none none 
8 pruritus 3 none 
9 none none 
10 none none 
11 none none 
12 none none 
13 none none 
14 WD WD 
15 vertigo 2 none 
16 none none 
17 diaphoresis -1 none 




Patient "4  = patient study number Probability that study drug 
ADR = adverse drug reaction was responsible for ADR = 
none = no side effects 6-7 definite 
WD = patient was withdrawn from study 4-5 probable 
0-3 possible 
< 0 unlikely 
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TABLE 10. ADVERSE DRUG REACTIONS AND PROBABILITY ASSESSMENT 
DURING THE 48 AND 72 HOUR PERIODS (continued) 















































































Patient # = patient study number 
ADR = adverse drug reaction 
none = no side effects 
WD = patient was withdrawn from study 
ND = no drug administered to the patient 
Probability that study drug 




< 0 unlikely 
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.TABLE 10. ADVERSE DRUG REACTIONS AND PROBABILITY ASSESSMENT 
DURING THE 48 AND 72 HOUR PERIODS (continued) 
Patient # 48 hour Probability 72 hour Probability 
ADR of ADR ADR of ADR 
31 headache -2 none 
dry mouth 0 
32 WD WD 
33 vertigo 5 dry mouth 5 
nausea 1 vertigo 1 
dry mouth 5 diaphoresis 5 
34 diaphoresis 3 none 
flushing 3 
pruritus 5 
dry mouth 4 
35 ND ND 
36 ND ND 
37 vertigo 3 vertigo 3 
dry mouth 3 
38 none none 
39 none none 
40 vertigo 4 WD 
confusion 4 
illusions 4 
dry mouth 3 
ABBREVIATIONS 
Patient # = patient study number 
ADR = adverse drug reaction 
none = no side effects 
WD = patient was withdrawn from study 
ND - no drug administered to the patient 
Probability that study drug 




< 0 unlikely 
APPENDIXES 
APPENDIX A 
CONSENT FORM USED IN STUDY 
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DOUBLE-BLIND RANDOMIZED COMPARISON OF BUTORPHANOL AND MORPHINE IN THE 
TREATMENT OF POSTOPERATIVE PAIN IN GERIATRIC PATIENTS 
Informed Consent 
You are scheduled for a surgical procedure following which you may 
require medication to lessen pain. Morphine and butorphanol are two 
potent analgesics which are commonly used to relieve moderate to 
severe pain. We are conducting research to compare the effectiveness 
and acceptability of these drugs in patients over the age of 60 
years. Potential advantages of butorphanol in the elderly compared 
to other potent analgesics include its lesser tendency to slow 
breathing at high doses and unchanged rate of removal from the body 
with aging. During the study, if you experience moderate to severe 
pain and request pain control medication, you will receive one or the 
other medication which will be Injected into your muscles. The 
dosage will be within normally accepted ranges and will vary with 
your response. The length of your treatment will depend upon your 
physician's assessment of your response to therapy and your requests 
for pain control. Neither you, the doctor, or the nurses will know 
which of the two medications you are taking until the end of the 
study. However, your physician has been advised and approves of your 
potential participation in this study. 
After the first injection of the medication you will be asked 
periodically over the next 6 hours to describe the amount of pain and 
pain relief you experience. Additionally, you will be asked to place 
a mark on a line to indicate the severity of your pain. These 
questions should take no more than 1 or 2 minutes for you to complete 
each time. 
In addition, you will be observed for any changes in the amount of 
oxygen in your blood. To accomplish this, a probe will be taped to 
the outside of your index finger or earlobe after the first dose of 
medication. You will be asked to wear this probe continuously for 6 
hours. If you continue to require pain control medication, the probe 
will remain attached for 24 hours, There is no discomfort associated 
with this probe. You will also be observed for any changes in 
drowsiness, blood pressure, heart rate or breathing rate. 
Butorphanol and morphine have been used clinically for several years 
in the United States and are approved by the Food and Drug Adminis-
tration (FDA) , The most common side effects experienced are sedation, 
nausea, dizziness, confusion, headache, sweating, and possibly slow-
ing of breathing. These resolve with discontinuation of the drug and 
are generally not considered serious conditions in the dose that will 
be administered to you. In the unlikely event that excessive sedation 
or breathing difficulty do occur, you will be given naloxone, an 
antidote for butorphanol or morphine, at the direction of the 
physician investigator. This antidote will be injected into your 
veins. At that point, your participation in this study will be 
terminated. If you develop severe nausea or vomiting during the 
trial, you will be given droperidol, a drug injected into your veins 
for nausea and vomiting control. Droperidol is used by doctors to 
relieve some of the discomfort and feelings of nausea and vomiting. 
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The risks from participating in this study Include the possibility of 
side effects from butorphanol or morphine as described above. In 
addition, any narcotic analgesic may lead to physical dependence but 
this is a rare complication. Injections into your muscles may be 
associated with tenderness, swelling, and redness. 
If there is any evidence that your pain is not being controlled by 
the study medications, or you are experiencing significant unpleasant 
side effects, the medication will be discontinued. Another analgesic 
will be prescribed for you by your doctor. Your participation is 
completely voluntary and you may be withdrawn at any time either by 
your decision or by that of the investigator. This will not result 
in any penalty or loss of benefits to which you are otherwise 
entitled. Neither will this affect your relationship with your 
physician, the investigators or this hospital. 
Benefits from participating in this trial include; 1) no charge for 
the narcotic analgesic during the first 72 hours postoperatively; 2) 
no charge for those laboratory tests performed which are for monitor-
ing or determining your eligibility; and 3) frequent monitoring of 
any pain you may experience. 
The data obtained from this study will be used for the advancement of 
medical and scientific knowledge, and as such may be considered for 
publication. In addition, representatives of Bristol Laboratories 
and the FDA may review all records collected during this investiga-
tion. All information obtained will remain confidential. 
In the event you sustain physical injury resulting from participation 
in this research project, the University of Utah will provide you, 
free of charge, emergency and temporary medical treatment not other-
wise covered by medical insurance. Furthermore, if your injuries are 
caused by negligent acts or omissions of University employees acting 
in the course and scope of their employment, the University may be 
liable, subject to limitations prescribed by law, for additional 
medical costs and other damages you sustain. If you believe that you 
have suffered a physical injury as a result of participation in this 
research program, please contact the Office of Research Administra-
tion, telephone number (801) 581-6903. 
Questions regarding this study may be asked at any time and should be 
directed to Dr. Ruthanne Ramsey (801-581-6304) or Dr. Perry Fine 
(801-581-6393). If no answer at the above numbers, questions may be 
asked 24 hours a day by calling (801) 582-1565 and asking the operator 
for pager #179. If you have questions that you do not wish to 
discuss with the investigators you may contact the Investigational 
Review Board at (801) 581-3655. 
I, , agree to participate in this 
research study which is entitled "Double-Blind Randomized Comparison 
of Butorphanol and Morphine in the Treatment of Postoperative Pain in 
Geriatric Patients". Upon signing this form, I acknowledge that I 
have had the opportunity to ask questions about the procedures, 
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risks, and other aspects that are involved in this trial. I under-
stand that I may withdraw my consent at any time without affecting 
the treatment I will receive. 
I given my permission for the information gained in this study to be 
released to the investigators, Bristol Laboratories, and the Food and 
Drug Administration with the understanding that my identify will not 
be revealed unless I expressly consent thereto. By signing, I 
acknowledge that I have received a copy of this consent form. 
Subject Signature Date 
Investigator Signature Date 
Witness Signature Date 
APPENDIX B 
PRESENT PAIN INTENSITY SCALE 
No pain (0) 








VISUAL ANALOG SCALE TO ASSESS PAIN INTENSITY 
Patient Name 
Date/time number 
Visual Analog Scale 
[ 
No Pain Pain as bad 
it could be 
SrivttaMkll K et al. O i l PhtrMCtl Tfc*r ltB3;14<2):234-23* 
APPENDIX D 
PAIN RELIEF SCALE 
Worse (-1) 
No relief (0) 
A little relief (1) 
Moderate relief (2) 
A lot of relief (3) 
Complete relief (4) 
Littman GS et al. Clin Pharm Ther 1985;38:16-23. 
APPENDIX E 
SEDATION SCALE 
None, fully awake (0) 
Drowsy, sleepy but responsive to 
various background stimuli (1) 
Somnolent, appears asleep but responds 






tin mictions.—After  you have familiarised  yourself  with tli* cut. begin at question 1. Answer it and 
each of  th» following  questions to which you art directed by the "go to" instructions. Fleas* re id each 
question carefully.  I I you do not understand a question, pleas* refer  ta the explication provided in the 
first  article of  this series. When you have completed the questionnaire, pleas* check your completed 
answers to be sure that you .have followed  the "go to" directions correctly. {Failure to follow  these 
directions is a common and important source of  error.) The completed scorn for  each of  tb« six axes 
should be placed in the appropriately numbered bo* below. The sum of  the scares is placed in the bo* 
. marked Total, and the likelihood of  ADR is interpreted according to the scoring transformation 
Instructions. 
Aii» i n nt iv v vi Tool 
Score • + • + • + • + • + • - • 
Scoring Twutut lualioe 
Namricsi Start Ordinal Category 
+7, +6 Definite 
+5, +4 Probable 
•3, +2, +1, 0 Possible 
<0 Unlikely 
L Previous General Experienc* With Um Drug 
L la the CM* widely known and universally accepted as an 
ADR to the suspected drug? 
• Yes Go to question 2 
Cf  No or DKt Co to question 3 
Z Is the CM known to occur at the dosage received in this case? 
• Yes Score +1 In Axis I box and go to 
question 5 
• No or DK Score 0 in Axis I box and go to 
question 5 
X Consult a recent edition of  the Physiciaia'Desk 
Reference  or American  Hospital  Formulary  Serocrt. Is 
the CM listed as an AD?, ta the suspected drug in the 
dosage received? 
• Yes Score 0 in Axis I box and go to 
question 5 
D No Go to question 4 
4 Has enough clinical experience accumulated with the 
drug so that most ADRs to it are very likely to have 
been previously reported? 
DYes Score-1 in Axis I bo* and go to 
question 5 
O No or DK Score 0 in Axis I box and go to 
question 5 
II. Altermlit* Eli«l<nie Candidates 
I» the CM a change (exacerbation, recurrence, 
complication, or new manifestation)  in a preexisting 
clinical condition, ie. a condition present before  the 
administration of  the suspected drag? 
• Yes Go to question 6 
• Mo or DK Go to question 9 
6. Is the preexisting condition commonly followed  by this 
type of  change? 
D Yes Score -1 in Axis II box and go to 
•question 14 
ODK -Go to question T 
P No Go to question 8 
7. Are there any new alternative candidates (illnesses 
developing after  the suspected drug was begun or recent 
diagnostic or therapeutic interventions jpart from  the 
suspected drag or other drugs) that could explain this 
change! 
• Yes Go to question U 
• No Score 0 in Axis n bon and go to 
question 14 
8. Are there any new alternative candidates (illnesses 
.developing alter the suspected drug was begun or recent 
diagnostic or therapeutic interventions apart .from  the 
suspected drug or other drugs) that could explain this 
change? 
• Yes Go to question U 
• No Score +1 in Axis II box and go to 
question 14 
9. Is the CM consistent in quality and severity with any 
new alternative etiologic candidates other than a 
preexisting condition, le. illnesses developing after  the 
suspected drug was begun or recent diagnostic or 
therapeutic interventionj-apart from  the suspected drug 
or other drugs? 
< O Jes Go to'question 10 
• DK Score 0 in Axis II box and go to 
question 14 
• No Go to question 12 
10. Was the CM consistent in timing with any of  these 
alternative candidates? 
• Yes Go to question It 
ODK Score 0 in Axis II box and go to 
question 14 
• No Go to question 12 
11. Is the CM commonly seta with any of  these alternative 
candidates? 
O Yes Score - 1 in Axil II box and go to 
question 24 
• No Score 0 in Axis IT box and go to 
question 14 
12. Does the CM commonly occur in this type of  patient in 
the absence of  rtcogniiable etiologic candidates? 
{Examples of  such phenomena include headache, 
fatigue,  and anxiety,) 
Q Yes or DK Go Lo question 13 
• No Score +2 in Axis II box and go to 
question 14 
' 13. Was a score of  +1 obtained on Axis I? 
• Yes Score +1 in Axis I I box and go to 
. question 14 
' • No Score 0 in Axil II box and go to 
question 14 
836 JAMA, Aua 17, 1979—Vol 242, No, 7 Adverse Drug Reactions—Hutchinson et al 
70 
til. Timing of  Etna 
14. I i the timing of  the sppcarance of  the CM relttiv* ta 
administration o£ the suspected drug difficult  or 
impossible to assess because the CM represent* an 
equivocal change in the preexisting clinical condition? 
• Yes Score 0 in Axis III box and go to 
question 13 
• No Go to question 15 
15. Is the drug-CM association so unusual as to prevent 
knowing what timing to expect (or an.ADR of  this type! 
• Yes Score 0 In Axis 111 box and go to 
question IS 
• Ho Go to question 16 
16. Was the timing inconsistent with an ADR to this drag? 
O Yes Score - 2 in Axis III box and go to 
question 18 
O No or DK Go to question 17 
17. Given the type of  CM, « u the timing not only 
consistent with, but as expected for  an ADR to this 
drug? 
• Yes Score +1 in Axis III box and go to 
question 18 
• No or DK Score 0 in Axis III box and go to 
question 18 
IV, Drug Le»eh end Evidence of  Omdese 
18. Is the CM a pharmacologic, ie, dose-reiated, type of 
manifestation? 
• Yes Go to question 19 
• No or DK Score 0 in Axis IV box and go to 
question 24 
19. Is the result available for  strum, urine, or other body 
fluid  level of  the drug or a metabolite of  the drug? 
• Yes Go to question 21 
• No Go to question 20 
20. Is there unequivocal evidence thai the amount of  drug 
received was an overdose for  this patient, eg, a blood 
glucose level of  30 mg/dL in a patient receiving insulin 
or discovery of  an empty pill battle of  a newly filled 
prescription for  the suspected drug? 
• Yes Score +1 in Axis IV box and go to 
question 24 
0 No Score 0 in Axis IV box and go to 
question 24 
21. Taking its timing into consideration, does this level 
definitely  support the diagnosis of  an overdose for  this 
patient? 
• Yes Score +1 in Axis IV box and go to 
question 24 
• DK Score 0 in Axis IV box and go to 
question 24 
• No Go to question 22 
22. Is the level strongly against the diagnosis of  overdose 
for  this patient? 
• Yes Go to question 23 
O No Score 0 in Axis IV box and go to 
question 24 
23. Is this CM likely to represent an idiosyncratic 
overreaction of  this paiient to the drug? 
O Yes Score 0 In Axis IV box and go to 
question 24 
O No Score - I in Axis IV box and go to 
question 24 
V. Dechalltn e^ 
24. Is dechallenge difficult  or impossible to assess because 
of  any of  the following? 
fa)  Death caused by, or secondarily consequent to, 
the CM. 
(b) An irreversible CM, eg, optic atrophy, aplastic 
anemia, loss of  a limb. 
(c) A CM whose resolution would not usually be 
altered by removal of  the causative agent, eg, 
stroke, myocardial infarction  (since, in these 
exaraplei, the resolution of  the organ damage 
would be expected to be independent of  drug 
withdrawal). 
• Yet Go to question 25 
• No or DK Go to question 26 
25. Is the total score on Axes I through IV t +3? 
• Yes Score+1 In Axis V box and go to 
question 47 
D No Score 0 in Axis V box and go to 
question 47 
26. Is the CM characteristically transient and episodic, eg, 
seizures, syncope, classic angina pectoris? 
"Characteristically transient and episodic" means that 
the phenomenon, by its very natare, almost always 
resolves quickly and spontaneously. CMs that eventually 
show themselves as self-limited  or that gradually 
subside on their own (eg, dyspnea, gastrointestinal 
bleeding, ataxia) would thus not qualify  as 
characteristically transient and episodic and should 
receive a "No" response. 
• Yes Go to question 27 
ONoorDK Go to question 30 
27. Was a pattern of  episodes established while the patient 
was taking the drug? 
• Yes Go to question 30 
• No Go to question 28 
28. Was the drug discontinued after  the CM appeared? 
O Yes Go to question 29 
• No Score. 0 in Axis V box and go to 
question 47 
29. Did the CM recur after  discontinuation? 
• Yes Score - 1 in Axis V box and go to 
question 47 
O No or DK Score 0 in Axis V box and go to 
question 47 
30. Is the CM a pharmacologic, ie, dose-related, type of 
manifestation? 
• Yes or DK Go to question 31 
• No Go to question 35 
31. Was the dosage substantially reduced without or before 
being discontinued? 
• Yes Go to question 32 
• No Go to question 35 
32. Was the dosage reduced while the CM was present (or 
while a patten of  episodes was occurring]? 
• Yes Go to question 33 
• No or DK Go to question 35 
33. Did the CM substantially diminish or disappear after 
dosage reduction but before  complete discontinuation? 
• Yes Go to question 41 
• No Go to question 34 
34. Was the drug subsequently discontinued? 
• Yes Go to question 36 
• No Score 0 in Axis V box and go to 
question 47 
35. Was the drug discontinued while the CM was present 
(or while a pattern of  episodes was occurring)? 
• Yes Go to question 36 
• DK Score 0 in Axis V box and go to 
question 47 
• No Go to question 38 
36. Did the CM diminish or disappear at any time after 
discontinuation of  the drug use? 
• Yes Go ta question 41 
• No Go to question 37 
37. Was the period of  obiervstion long enough to be sure 
that the CM would not subsequently diminish or 
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disappear in a time compatible with an effect  of  drug 
withdrawal? 
• Yes Score -1 in Axis V box and go to 
question 47 
• No Score 0 in Axis V box and go to 
question 47 
38. Did the CM substantially diminish or disappear while 
the patient was taking the drug? 
• Yes Go to question 39 
• No Score 0 in Axis V box and go to 
question 47 
39. Was an agent or maneuver administered that was 
specifically  directed against the GM and that usually 
produces the degree and rate of  improvement observed 
in this case? (A nonspecific  therapeutic measure would 
not qualify  for  a "Yes" response to this question. Thus, 
the administration of  intravenous fluids  would result in 
a "No" response if  the CM were coma caused by a drug 
overdose but a "Yes" response if  the CM were 
dehydration.) 
• Yes Score 0 in Axis V box and go to 
question 47 
• No Go to question 40 
40. Is the improvement in the CM most likely caused by the 
development of  tolerance to the drug, and is tolerance a 
well-described phenomenon with the drug? 
• Yes Score 0 in Axis V box and go to 
question 47 
• No Score -1 in Axis V box and go to 
question 47 
41. Was the CM (or the established pattern of  episodes) 
constant or progressing at the time of  dechallenge? 
• Yes Go to question 42 
• No Score 0 in Axis V box and go to 
question 47 
42. Were the degree and rate of  diminution or 
disappearance of  the CM as expected for  an effect  of 
drug withdrawal? 
• Yes Go to question 43 
• No Score 0 in Axis V box and go to 
question 47 
43. Was an agent or maneuver administered that was 
specifically  directed against the CM and that usually 
produces the degree and rate of  improvement observed 
in this case? (A nonspecific  therapeutic measure would 
not qualify  for  a "Ye9" response to this question. Thus, 
the administration of  intravenous fluids  would result in 
a "No" response if  the CM were coma caused by a drug 
overdose but a "Yes" response if  the CM were 
dehydration. I 
• Yes Go to question 44 
• No Go to question 45 
44. Would this agent or maneuver be expected to improve 
this type of  CM regardless of  whether or not it was 
caused by the suspected drug? (The administration of  a 
narcotic antagonist to a patient with a CM of  coma 
caused by morphine overdose would result in a "No" 
response, because the narcotic antagonist wiil only 
improve coma if  it is caused by a narcotic.) 
• Yes Score 0 in Axis V box and go to 
question 47 
• No Go to question 45 
45. Was there a good alternative etiologic candidate that 
resulted in a score of  -1 on Axi9 II? 
• Yes Go to question 46 
• No Score +1 in Axis V box and go to 
question 47 
46. Was there an unequivocal improvement in or 
disappearance of  this alternative etiologic candidate 
that could explain the improvement in the CM? 
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• Yes Score 0 in Axis V box and go to 
question 47 
• No Score+l in AxisV box and goto 
question 47 
VI. Rechallenge 
47. Was the drug discontinued and then read ministered? 
• Yes Go to question 50 
• No or DK Go to question 48 
48. Is the GM a pharmacologic, ie, dose-related, type of 
manifestation? 
• Yes Go to question 49 
• No or DK Score 0 in Axis VI box and go to 
question 57 
49. Was the dosage substantially increased after  previous 
reduction in dosage? 
• Yes Go to question 50' 
• No or DK Score 0 in Axis VI box and go to 
question 57 
50. Was the CM either progressing or at such a level of 
severity that any recurrence or exacerbation would be 
difficult  to appreciate? 
• Yea or DK Score 0 in Axis VI box and go to 
question 57 
• No Go to question 51 
51. Did the CM recur or clearly exacerbate after 
rechallenge? 
• Yes Go to question 52 
• DK Score 0 in Axis VI box and go to 
question 57 
• No Go to question 53 
52. Have any new clinical conditions or recent diagnosticoi 
therapeutic interventions occurred (including drugs 
begun since the appearance of  the original CM) that 
could explain this recurrence or exacerbation? 
• Yes Score 0 in Axis VI box and go to 
question 57 
• No Score +1 in Axis VI box and go to 
question 57 
53. Is there unequivocal evidence that the dosage or 
duration of  drug administration on rechallenge was lea 
than the dosage and duration suspected of  causing the 
original CM? 
• Yes Go to question 54 
• No Go to question 55 
54. Is the original CM a pharmacologic, ie, dose-related, 
type ol' manifestation? 
• Yes Go to question 56 
• No or DK Go to question 55 
55. Did the patient receive another agent or maneuver thil 
would be expected lo prevent recurrence or exacerbmiot 
of  the CM? 
• Yes Score 0 in Axis VI box and go U> 
question 57 
• No Score -1 in Axis VI box and sou 
question 57 
56. Was rechallenge subsequently attempted with a higtif 
dosage? 
Q Yes Go back lo question 50 
• No Score 0 in Axis VI box and go ui 
question 57 
57. Stop reading the questionnaire, add up the scores in il* 
six axis boxes on the cover sheet, and place the sum11 
the box marked "Total." 
•Abbreviation CM indicates clinical manifestation,  the abnormal JiV 
i\ mptom, or laboratory test, or cluster uf  abnormal signs, symptom^ 
testa, that is beinif  considered as a possible adverse drug reacnon 
t.Abbreviation UK indicates Do not know, this answer snouia w F1' 
when no djia are available for  the qi/estion beinn answered, or 
quality o( the data does noi allow a r.rm "Yes" or "No" response. 
iWhen Ihese are not available an equivalent reference  source ma) " 
used. 
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APPENDIX 6: TIHE LINES FOR THE OBSERVATION PERIOD 
t = tlmt (hours) 
D = dose (ml) 
Pi= nam Intensity : (0) No PUn. ( 0 mid Pain, (2) Discomforting. 
(3) Dlstresing. (4) Horrible, (5) Exeruletlng 
PR=paln relief: (-1) worse, (0) No Relief, (1)A Little Relief. (2) 
Moderate Relief. (3) A Lot of Relter. (4) Complete Relief 
PA=poln enelofl (mm) 
i = sedation: (o) None ,fully awalse, (t) Drowss. but responsive, 
(2) somnolent, reponds te dlreet commands. (3) Asleep 
Pt*l 
t U i I 1 1 1 1 1 1 
0 1 2 3 4 5 6 
D X M M X I I I I 1 
1ml 0.5ml 
PI LI I 1 I 1 1 1 1 
4 3 4 
PR|_U__U 1 1 1 1 1 
I -1 
PA U - J J J 1 1 1 1 1 
90 74 84 
s L 4 J J J I 1 I I I 
2 2 2 1 
Pt *2 
t L L X J J 1 1 1 1 1 
0 1 2 3 4 5 6 
D X I I I .1 XI 1 1 1 1 
lm) 0.5ml 
PI I I I I I 1 1 1 1 1 
2 2 2 5 
PR1 I M I 1 1 1 1 1 
2 1 -1 
P A l J J J .J I I 1 I 1 
73 61 81 85 
s L U - U 1 1 1 1 1 
1 1 1 0 0 
Pt *3 
i L L I J J 1 1 I I I 
0 1 2 3 4 5 6 
D X J J J J |_X | | | | 
1 mi 0.5ml 
PI L L L L I 1 I I I I 
4 4 3.5 3 
PR U-IJ-I 1 I I I I 
1 1 0 
PA U J J J 1 | I | I 
68 77 64 61 
s LU-I-I 1 I I I I 
2 3 3 3 0.5 
Pt*4 
i U J J J 1 I I I I 
0 1 2 3 4 5 6 
D X | | | I IX I I I I 
1ml 1 mi 
PI I J J J J I I I I I 
3 1 0,5 3 
P R L L L L I I I I I I 
2 3 I 
P A l J J J J I I I I I 
71 24 26 74 
5 U J J J I I I I I 
0.5 11.75 1.5 1 
Pt *5 
I I—l—l—l—l I I I I I 
0 1 2 3 4 5 6 
D X J J J J L X I I 1 1 
imi I ml 
PI L L L L I I 1 1 1 1 
3 2 1 3 
PR U J J J I 1 1 1 1 
2 3 2 
P A U J J J I I I 1 1 
60 
s L L L L I 1 1 1 1 1 
3 3 3 3 3 
75 
Pt* 
i y j j - i 1 i 1 i i 
0 1 2 3 4 5 6 
D X-LLIJ 1 LX 1 I I 
1ml 0,75ml 
PI l - U J J 1 1 1 1 I 
2.5 1 3 3 
P R L L L L I 1 1 1 1 1 
P A L L L U I I I 1_ 
39 26 38 47 
s I J J J J 1 1 I L 
2 3 3 3 3 0 
Pt *7 
t U - U - l 1 I I L 
0 1 2 3 4 5 
D X—I—I—I—I 1 1 X _ J L 
1 ml 1 mi 
PI L L L U 1 I 1 L 
4 3 3 3 2 
PR U - U - l I 1 1 L 
P A L U - U I L 
73 54 60 54 40 
s L U - U 1 !_ 
1,75 1.50 2 0 1.75 
Pt*8 
I f.iMinw f i—j—•ni| —i | iimmimmmmmmmmmmmmmmm  | n—^— 
0 1 2 3 
D x_u_u LX I. 
1ml 1ml 
PI LI-U-I I L 
3 1 1 3 
PR U L L L I I L 
3 3 0 
PALLLLI 1 1-
15 10 90 
s LLLI-I 1 L 
1.5 2 1.5 I I 
Pt *S> 
i L U L L ! 1 I. 
0 1 2 3 
D X J J J J X I L 
1ml l ml 
PI L L I J J 1 L 
2 1 1 
P R U J J J I L 
P A L L L L I 1 J 1 I 1 
24 18 12 
s L L L I J I 1 I I 1 
0 0.5 0 0 
Pt'10 
i L L L L I I 1 I I I 
0 1 2 3 4 5 6 
D X J J J J X 1 1 1 1 1 
1 ml 0,75ml 
Pi L L L L I 1 1 1 I 1 
3 2 3 
PRLIJ-IJ I 1 1 I 1 
PALIJ-LI 1 
76 37 
s L L L L I 1 
2 3 3 2 
Pt*11 
i L L L L I I 
0 I 2 
D X J J J J IX— 
1 ml o,75mi 
PI L L L L I I 
4 3 2 2 
P R L L L L I I 
0 2 3 
P A J J J J J 1 
100 70 79 41 
s L L L L I 1 
11.5 1 1 1 
Pt*12 7 7 
i U J - L I 1 1 I I I 
0 1 2 3 4 5 6 
D X—I—1—I—IX I I | I | 
1ml I ml 
PI U J J J I I I I I 
5 3 4 
P R l J J J J | 1 | | | 
1 2 
P A l J J J J 1 1 I 1 I 
91 69 50 
s U - L I J I I I I I 
1.5 1 1.5 1.5 
Pt * 13 
t U J J J I I I I I 
0 1 2 3 4 5 6 
D X J J J J I |_X | 1 1 
iml 0.5ml 
PI U J J J I I I 1 1 
3 1 1 1 1 
P R l J J J J I I I I I 
3 3 3 3 
P A L L L L I I I I I 1 
28 19 9 12 31 
s L L L L I I I I I 1 
1 3 3 3 3 2 
Pt* 14 
i L L L L I I I 1 1 1 
0 1 2 3 4 5 6 
D X J J J J X | | | 1 1 
iml I mi 
PI L L L L I I 1 1 1 1 
PRUJJ-I I I 1 1 —I 
1 2 
P A l J J J J I I 1 1 1 
69 78 
s L L L L I I 1 I 1 1 
0 0 3 2 
Pt*15 78 
i L U - U 1 1 I 1 I 
0 1 2 3 4 5 6 
D X J J J J 1 I I | | 
iml 
pi L L L U I I I I I 
2 1 1 0 0 1 1 0 
P R U J J J 1 1 1 | | 
2 2 1 3 4 
P A L U J 1 1 1 I I I 
24 12 15 2 5 3 3 2 
s L L L U I I I I I 
0 0 0 0 0 0 0 0 
Pt*16 
I l-LLLI I I I I I 
0 1 2 3 4 5 6 
D X J J J J 1 1 1 1 I 
Iml 
PI L L L U I I I 1 I 
3 2 0 0 0 1 1 
P R L L L L I I I I I I 
2 4 4 4 2 
P | j j i— | | i»im| |.I—i — MII..II-.| 
42 22 7 0 21 19 
s L L L U I I I 1 1 
13 3 3 3 I 3 
Pt* 17 
i L L L U 1 I I I 1 
0 1 2 3 4 5 6 
D X J J J J X 1 1 1 1 1 
iml o,75mi 
PI L L L U I 1 1 1 1 
P i l i i u I , , I I 
1 2 
P A L L L U I 1 I 1 1 
90 82 51 
s L L L U 1 1 1 1 1 
0 11 2 
Pt* 18 
i U J - I - I I I 1 I I 
0 1 2 3 4 5 6 
D X J J J J X 1 IX 1 I | 
tml Iml iml 
PI L L I J J I I 1 I I 
5 5 4.5 4 3 
P R l J J J J 1 | I | | 
P A l J J J J . 
0 0 
P A l J J J J . 
93 86 84 
5 1 1 1 1 !„„,„ 
0,75 .5 1 0.5 
92 94 92 72 58 
s L L L L I 1 L 
0 0 0 0 I 0 
Pt * 19 
i U J - L I I I I-
0 1 2 3 4 
D X J J J J I I XJ. 
iml tml 
PI L L I J J 1 1 L 
4 3 2 2 2 
P R U J J J 1 L 
2 
P Al m  1-1 I — | mmm  | | • ——mum | HI i 
72 49 35 29 31 
s L L L L I I I -
3 3 3 3 3 3 
Pt*20 
t L L L L I I I I I. 
0 1 2 3 4 5 
D X J J J J X I I I I. 
Imi 1ml 
PI U J - L I I 1 1 L 
5 4 4 
P R U J J J I I I I -
i l - U - l - l 1 1 I [ I 
0 1 2 3 4 5 6 
D X J J J J 1 X—I I | | 
iml Iml 
PI U J J J 1 I I I I 
2 1 1 5 
P R l J J J J 1 1 I I I 
PAl—l—IJJ 1 1 | U 
65 26 64 
s L L L L I 1 I I U 
13 3 3 3 
Pt*22 
i L L I J J I I I I-
0 1 2 3 4 5 
0 X J J J J IX I I L 
iml 1 ml 
PI U J J J I I 1 L 
3 2 2 3 P R l J J J J I 1 1 L 
3 1 1 
P A L I - L L I I 1 I L 
72 74 43 77 
s U J J J I I 1 L 
2.5 2,5 3 3 2 
Pt*23 
i L L L L I I 1 1 1-
0 1 2 3 4 5 
D X J J J J - X 1 1 1 1. 
iml iml 
PI L L I J J I I I L 
3 3 3 
P R l J J J J I 1 1 L 
P A L L U J -
54 62 64 
S L L L L I — 
0 0 0 0 
3 3 2,5 
PRLI 1 I J — 
PALLLLL 
Pt* 
i L L L U 1 I | f | 
0 1 2 3 4 5 6 
D X J J J J I |__X | J | 
iml iml 
PI LLLL I 1 I | | i 
64 52 26 30 73 
s LLLL I 1 L 
0 12 2.5 2 1 
Pt*25 
i LLLLI I L 
P A L J J J J 1 L 
9496 96 97 96 99 
s L U - U 1 L 
1 2 1 1.5 1 1 
0 1 2 3 4 5 6 
D X J J J J X 1 | | | | 
iml iml 
PI U - L U 1 1 I I I 
4 3 3 
PRLLLLI 1 1 I I I 
1 i 
PALLLU I I I I I 
87 77 63 
s LLLLI I I I I 1 
0 0 0 0 
Pt*26 
t LLLLI I 1 1 1 1 
0 1 2 3 4 5 6 
D X J J J J I IX 1 1 1 
1ml 0.5ml 
PI U J J - I I 1 1 1 1 
• 3 1 1 1 2 
P R I J J J J I 1 1 1 1 
Pt *27(pt could not vituiltii the peln arwlog scale) 
I U J J J 1 I I I I 
0 1 2 3 4 5 6 
D XJJJJ 1 1 1 1 1 
iml 
Pi I I I I I 1 I I I I 
4 4 1 1 2 1 2 
PR I I 1 1 1 1 I 1 I I 
1 1 1.5 3 3 3 
s M i l l 1 1 1 1 1 
1.52.5 3 3 3 3 3 3 
Pt "2d 
% U J J J 1 1 1 
0 1 2 3 4 5 6 
D XJJJJ 1 1 IX 1 1 
iml iml 
PI U J J J 1 1 1 1 1 
4 1 0 
PRlJJJJ. 
PAlJJJJ 1 L 
53 25 10 11 91 85 
s U J J J 1 1 L 
0 1 0 
Pt *29 
t U J J J 1 1 1 1 1 
0 1 2 3 4 5 6 
D XJJJJ 1 1 IX 1 1 
iml iml 
PI I I. I M I I I 1 1 
3 2 1 1 1 1 
P R l J J J J 1 1 1 1 1 
2 2 2 2 2 
PALII I I 1 1 1 1 1 
51 23 21 
s LI. 1 1 I J 1 1 1 1 
1 I 2 2,5 3 3 3 
Pt *30 
t L U - U I I 1 1 I 
0 1 2 3 4 5 6 
D X J J J J X 1 I 1 1 I 
iml iml 
pi LI_U_I 1 I I l_ | 
4 3 4 4 3 3 
P R L U - L I 1 I I I I 
1 o 
PALLI I I I I I I 
95.5 82.5 96 
s L U I L 1 1 1 
0 0 0 0 
Pt *31 
t L L L U 1 1 1 1. 
0 1 2 3 4 5 
d X J J J J 1 1 1 1 
iml 
pi L L L L I I I I L 
35 1 1 0 0 0 0 
P R L L L L I 1 1 1 L 
3 3 A 4 4 4 
PALLLU I 1 I 1-
79 14 5 2 0 0 0 0 
s L L L L I I I I 1 1 
0 3 2 2 2 2 2 0 0 
Pt *32 
t L L L U I I I— 1 I 
0 1 2 3 4 5 6 
D X-LLLIX I 1 1 1 1 
1ml 1ml 
PI L U - U I 1 1 1 1 
4 4 4 * 
P R L L L L I I I I I I 
0 0 
PALLI—LI I 1 1 1 1 
68 B7 90 
s L L L U I I I 1 I 
0 0 0 1 
84 Pt*33 
T U J J J 1 I I I I 
0 1 2 3 4 5 6 
D XJJJJ IX 1 1 | | 
Iml Iml 
PI U J J J 1 1 1 1 I 
5 3 3 3 
PRJJJJJ 1 1 1 1 I 
2 2 2 
P A U J J J I I I I I 
92 60 45 50 
s U J J J I 1 I I I 
0 1 1 1 1 
Pt-34 
i U J J J 1 1 1 1 1 
0 1 2 3 4 5 6 
D X J J J J IX 1 1 1 1 
iml iml 
PI U J J J 1 1 1 1 1 
3 2 3 3 
P R l J J J J I I 1 1 I 
3.5 4 4 
P A j J J J J 1 | 1 1 1 
71 17 84 
s U J J J I I 1 I J 
0 3 3 3 3 
Pt*35 
i U J J J I J 1 1 1 
0 1 2 3 4 5 6 
D X J J J J I IX I I I 
iml 1ml 
PI U J J J I I I I I 
2 2 1 2 2 
P R U J J J I I I I I 
P A U J J J I U 
30 19 15 20 20 
s I J J J J I l_ 
0 3 3 1 3 3 
85 
Pt *36(pt did not eoopenatt witn tr»t petn rtlftf  icon) 
t M i l l 1 1 1 I I 
0 1 2 3 4 5 6 
D XJJJJ 1 1 1 1 I 
Iml 
Pll 11 11 1 1 I | I 
4 2.5 2 2 2 
PAJ I I I I 1 1 1 | 1 
85 4a 61 63 
s M i l l 1 1 1 1 I 
0 1 1 3 2 
Pt *37 
t 1 1 1 1 I 1 1 1 1 1 
0 1 2 3 4 5 6 
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DESCRIPTION OF PATIENT SPECIFIC ADVERSE DRUG REACTIONS 
Patient Description 
#1 65 yo This patient complained of nausea at Ih and had nausea 
and vomiting for the next 24h but was not treated with medication. 
At 48h she was experiencing some itching. At 72h she had no 
complaints. Total doses: 17. Total mis: 16. 
#2 60 yo At 5h after the initial dose the patient's son asked that 
she be removed from the study because he felt she was not receiving 
adequate pain relief. She was taken off the study at this time. The 
patient did have some itching the evening after surgery but it is 
unknown if this was related to the study drug or the other narcotics 
which she was receiving. Total doses: 2, Total mis: 2. 
93 65 yo This subject complained of nausea initially and at 2h 
after the initial dose. At 24h she had some dysphoria. No other 
side effects were noted throughout the remainder of the study. Total 
doses: 14. Total mis: 11. 
#4 67 yo She complained of being cold during the observation 
period. At 24h she had been nauseated twice without vomiting. She 
still felt cold and had experienced some dizziness. She had no 
further complaints or problems. Total doses: 13. Total mis: 12.5. 
If5  62 yo At 24h the surgical team stated concern over patient1 s 
continued somnolence at 1800 when her last dose had been given at 
0645. She was drowsy, but completed oriented, She received another 
dose at 2100 and her drowsiness increased, but was still arousable 
and oriented, The surgeons decided to removed her from the study at 
this time. Total doses: 4. Total mis: 4. 
#6 66 yo At 24h the patient claimed to feel "very worn out". At 
48h he had an incident of slight nausea, For the rest of the study 
he remained without further problems. Total doses: 4. Total mis: 
3.25. 
7 1 7° T h i s Patient had no side effects or complaints throughout 
the study. Total doses: 2. Total mis; 19,5. 
#8 66 yo At 24h she complained of itching all over which started 
the morning after surgery. At 48h and 72h the pruritus was less. 
Total doses: 9* Total mis: 9. 
#9 69 yo At 24h he experienced some nausea after waking. No other 
side effects were noted at 48h and 72h. Total doses: 5. Total mis: 
3.25. 
#10 64 yo At 24h he had sweating, a headache and some pruritus. 
He also had a hand tremor which had been present for six months. At 
48h and 72h the tremor was still present, but he had no other 
complaints. Total doses: 13. Total mis: 10.75. 
DESCRIPTIONS OP PATIENT SPECIFIC ADVERSE DRUG REACTIONS 
(continued) 
#11 64 yo The subject experienced no side effects throughout the 
study. Total doses: 4. Total nils: 3.25. 
#12 71 yo At 24h he had a slight itch and tingling in his head and 
one episode of nausea. He also noted some sweating, but felt this 
was due to his slight fever. At 48h he complained of having bad 
dreams. Total doses: 18. Total mis: 18. 
#13 78 yo During the observation period and at 24h he had some 
nausea and blurred vision. At 48h his blurred vision had decreased. 
Total doses: 11. Total mis: 6.5. 
#14 66 yo The study began at 1630, The patient's son asked that 
he be withdrawn from the study at 1830 because he felt he was not 
receiving adequate pain relief. Total doses: 1. Total mis: 1. 
#15 80 yo During the observation period, the patient was having 
blurred vision with difficulty focusing and a frontal headache. At 
24h she had a little nausea, felt worn out and did not feel like 
eating. She als o claimed to have a slight amount of pruritus and a 
dry mouth. At 48h she had dizziness when she sat up quickly. The 
pruritus she was experiencing across her back, she claimed to have 
when in the hospital in the past. At 72h she was discharged to home. 
Total doses: 5. Total mis: 5. 
#16 70 yo Patient was nauseated in the recovery room and was 
treated with droperidol 0.25 ml. At 24h she continued to have some 
nausea which resolved by evening. At 48h she had a headache which 
she attributed to positioning. She also had palpitations and some 
nausea due to the fumes from the cleaning fluids being used in the 
hospital. Total doses: 1. Total mis: 1. 
#17 70 yo At 24h she had some mouth dryness following the study 
drug injections. At 48h she had a swollen throat due to a Candida 
infection, and some sweating. She was receiving clortrimazole 
troches as treatment. At 72h her sore throat was her only complaint. 
Total doses: 7. Total mis: 5:25. 
#18 78 yo Patient vomited several times before the study drug was 
given and was treated with droperidol 0.25 ml for one dose. At 24h 
her nausea had improved, but she had a small amount of vomiting and 
received droperidol 0.25 ml for one dose. She also experienced some 
insomnia due to her pain, some heartburn and a very dry mouth. At 
48h she had some pruritus on her buttocks. At 72h she claimed she 
felt tired and had one wave of nausea that day. Total doses: 17. 
Total mis: 17. 
DESCRIPTIONS OF PATIENT SPECIFIC ADVERSE DRUG REACTIONS 
(continued) 
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#19 71 yo During the observation period he stated his pain felt 
nauseating. At 24h he had trouble sleeping, but said this was 
consistent with other hospitalizations. He also experienced some 
sweating and a very dry mouth. At 48h he complained of having some 
strange dreams the previous night. He attributed the sweating and 
slight pruritus he was experiencing to the increased heat in his 
room. At 72h his only complaint was tinnitis which he noted he 
always has in the hospital. Total doses: 18. Total mis: 17.75. 
#20 67 yo During the observation period he complained of some 
nausea. At 24h he had some dizziness, still nauseated and was being 
medicated with droperidol 0.25 ml for two doses. At 48h he had no 
complaints. Total doses: 13. Total mis: 13. 
#21 85 yo Experienced some nausea during the observation period 
and was treated with promethazine 25 mg for one dose. At 24h she was 
removed from the study due to central nervous system effects. She 
was very agitated, rude and contradictory. She had a very abrupt 
change in character. Total doses: 5. Total mis: 3. 
#22 60 yo During the observation period he was disoriented and 
groggy. At 24h he had a headache, dizziness, some dreams and felt as 
if he had a heavy chest. At 48h he still complained of a headache, 
trouble sleeping and many dreams, but claimed to be less sedated than 
he had been. A medical student called and asked that he be removed 
from the study since he was having pain, but did not want to take 
pain medication because he claimed it made him disoriented. Total 
doses: 11. Total mis: 10. 
#23 73 yo Patient complained of hallucinations and bad dreams 
during the first night of the study. He had no other complaints 
throughout the study. Total doses: 21. Total mis: 19.5. 
#24 75 yo During the observation period he was having some eye 
Irritation probably due to his 0„ mask. He also experienced some 
dizziness after one injection of s'tudy drug. He received only three 
doses postoperatively and had no other complaints. Total doses: 3. 
Total mis: 2.5. 
#25 66 yo This patient had nausea 15 minutes after the second dose 
with no ernes is which continued into the night. At 24h she was still 
having some nausea which she noted would come and go. As a result of 
her nausea she refrained from taking fluids and consequently was 
experiencing a dry mouth and lethargy. She also had trouble sleeping 
the first night due to the pain. At 48h she had slept better, was 
having no nausea and her mouth dryness had improved. She did have 
some pruritus all over which began the morning of the second day. At 
72h she was still experiencing some pruritus, but had no other 
complaints. Total doses: 10. Total mis: 10. 
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#26 74 yo She had an episode of nausea in the recovery room and 
once during the observation period 2h after the first dose. At 24h 
her nausea had improved and she had vomited once in the morning. She 
also experienced some confusion in the night, and some dizziness. 
She had dripping perspiration during the night and awoke with a head-
ache. At 48h she experienced some slight nausea, but no vomiting and 
was able to eat. She experienced some bad dreams the previous night. 
She also complained of a very dry mouth. At 72h she claimed she felt 
some lethargy, nervousness and anxiety. Also, she noted some sweati-
ness and itching. The pruritus was a common problem for her in the 
hospital. Her dry mouth continued to be a problem. Total doses: 11. 
Total mis: 9. 
#27 63 yo Her only complaint was mouth dryness for the 72h period, 
but this was probably due to her nasogastric suction. Total doses: 
15. Total mis: 7.125. 
#28 71 yo At 24h had problems sleeping due to nurse's monitoring 
and a dry mouth secondary to being NPO. She only received two doses 
postoperatively, both within four hours. Total doses: 2. Total 
mis: 2, 
#29 61 yo He vomited ten minutes before the first dose of the 
study drug and was treated with droperidol 0.25 ml for one dose. At 
24h he experienced some dizziness and insomnia and nausea, but did 
not have any vomiting. He had complaints of a dry mouth, but was 
also on a scopolamine study. At 48h he had not received additional 
study drug since the morning after surgery, but was still having some 
nausea and a little dizziness. His mouth dryness was still present. 
Total doses: 4. Total mis: 3. 
#30 60 yo During the observation period he noted some dizziness. 
At 24h he was nauseated and had vomited three times. He was treated 
with droperidol 0.25 ml for one dose. He felt that he was having 
funny Illusions of having seen something before. He was also having 
mouth dryness, but attributed this to his radiation therapy. At 48h 
he still complained of some nausea and a very dry mouth. At 72h he 
had no complaints. Total doses: 14. Total mis: 13. 
#31 61 yo During the observation period she felt some nausea 
before the study medication was given. This resolved without medica-
tion. At 24'n she complained of tinnitus and compression in her ears 
and felt this was probably due to a cold. She also had some mouth 
dryness, but had not had any fluids that day. At 48h she had a 
slight headache with a little mouth dryness. At 72h she was dis-
charged to home. Total doses: 10. Total mis: 9. 
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#32 67 yo This subject had a headache after surgery, before she 
was medicated with the study drug, which returned during the observa-
tion period. At 24h she was complaining of a severe headache that 
was not relieved by the study medication, but was identical to oth&r 
headaches she had experienced when she was taken off her Premarin . 
She also had nausea and vomiting during the night and this morning 
and was treated with droperidol 0.5 ml for two doses. She felt tired 
and had a dry mouth, but had only been taking sips of fluids. She 
also complained of heart palpitations which seem worse than those she 
usually had experienced. Due to her headaches not being relieved she 
asked to be withdrawn from the study. Total doses: 9. Total mis: 9. 
#33 70 yo At 24h he complained of some dizziness when he got up 
from bed, flushing, and a dry mouth. At 48h he had some nausea and 
dizziness when he got up from bed and still was experiencing mouth 
dryness. At 72h the dizziness and dry mouth were still present and 
he was experiencing some diaphoresis. Total doses: 24. Total mis: 
24. 
#34 66 yo He experienced some nausea and vomiting fifty minutes 
after the first dose. At 24h he experienced nausea and vomiting at 
breakfast. At this time he also complained of having some confusion, 
feeling "dopey", some scalp pruritus and a dry mouth, but he noted 
that the later was always present in the hospital. He also had some 
insomnia which he claims is not uncommon. At 48h he complained of 
excessive flushing, diaphoresis and scalp pruritus and continued to 
have mouth dryness as well. At 72h he had no complaints. Total 
doses: 16. Total mis: 16. 
#35 63 yo During the observation period he woke up startled and 
panicked. At 24h he had some insomnia and a dry mouth which he 
claims to always have in the hospital. He had only two doses of the 
study drug, both were within three hours of surgery. Total doses: 2. 
Total mis: 2. 
#36 87 yo She complained of a dry throat and mouth during the 
observation period and a humidifier was ordered. At 24h she had some 
nausea and vomiting and mouth dryness. At 48h she was discharged 
from the hospital. Total doses: 4. Total mis: 3. 
#37 67 yo She was not receiving adequate pain relief and her dose 
was increased to 1-2 ml of the study drug. Subsequently, she claimed 
to have good pain relief. At 24h-72h her only complaint was some 
vertigo when getting up from bed and mouth dryness at 48h only. 
Total doses: 22. Total mis: 24.5. 
#38 77 yo She had some nausea and mouth dryness at 24h, but was 
without complaints throughout the remainder of the study. Total 
doses: 21. Total mis: 21. 
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(continued) 
#39 70 yo In the recovery room she had some nausea and was taking 
many ice chips postoperatively. She vomited three times and was 
treated with droperidol 0.5 ml for two doses. At 24h the nausea and 
vomiting continued and she also noted a dry mouth. She received 
droperidol 0.25 ml and metoclopramide 5 mis for one dose. At 48h she 
had no complaints and was taking no pain medications. Total doses: 
2. Total mis: 1.5. 
#40 73 yo At 24h he experienced some nausea without vomiting and 
was treated with droperidol 0.25 ml for two doses. He was hyper-
glycemic and required insulin. By history his diabetes was normally 
controlled by diet. He had a dry mouth and some confusion which 
presented by conversations about his dog. He was also having hallu-
cinations about an unknown man standing behind his bed. At 48h he 
claimed that he felt "like he was falling" and he continued to be 
confused. He was still having hallucinations and a dry mouth and 
received 0.4 mg of naloxone. He was later removed from the study due 
to his low glucose and central nervous system manifestations and he 
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